



## Clinical trial results:

### A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

#### Summary

|                          |                      |
|--------------------------|----------------------|
| EudraCT number           | 2020-000440-63       |
| Trial protocol           | HU DE PT AT CZ PL IT |
| Global end of trial date | 12 June 2023         |

#### Results information

|                                |                                                                                                                                                             |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Result version number          | v2 (current)                                                                                                                                                |
| This version publication date  | 04 September 2024                                                                                                                                           |
| First version publication date | 26 June 2024                                                                                                                                                |
| Version creation reason        | <ul style="list-style-type: none"><li>• Correction of full data set</li></ul> There are a few small corrections that need to be made to the results record. |

#### Trial information

##### Trial identification

|                       |         |
|-----------------------|---------|
| Sponsor protocol code | GR41984 |
|-----------------------|---------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04740905 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |                                                                                                           |
|------------------------------|-----------------------------------------------------------------------------------------------------------|
| Sponsor organisation name    | F. Hoffmann-La Roche, Ltd.                                                                                |
| Sponsor organisation address | Grenzacherstrasse 124, Basel, Switzerland, 4058                                                           |
| Public contact               | F. Hoffmann-La Roche, Ltd., F. Hoffmann-La Roche, Ltd., +41 616878333, global.trial_information@roche.com |
| Scientific contact           | F. Hoffmann-La Roche, Ltd., F. Hoffmann-La Roche, Ltd., +41 616878333, global.trial_information@roche.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |              |
|------------------------------------------------------|--------------|
| Analysis stage                                       | Final        |
| Date of interim/final analysis                       | 12 June 2023 |
| Is this the analysis of the primary completion data? | No           |
| Global end of trial reached?                         | Yes          |
| Global end of trial date                             | 12 June 2023 |
| Was the trial ended prematurely?                     | No           |

Notes:

## General information about the trial

Main objective of the trial:

The primary efficacy objective for this study is to evaluate the efficacy of faricimab 6 mg IVT Q4W compared with aflibercept 2 mg IVT Q4W on the basis of the change from baseline in BCVA at Week 24.

Protection of trial subjects:

This study was conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. All participants were required to read and sign an informed consent form prior to participation in the study.

Background therapy: -

Evidence for comparator: -

|                                                           |               |
|-----------------------------------------------------------|---------------|
| Actual start date of recruitment                          | 02 March 2021 |
| Long term follow-up planned                               | No            |
| Independent data monitoring committee (IDMC) involvement? | Yes           |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Argentina: 68          |
| Country: Number of subjects enrolled | Australia: 14          |
| Country: Number of subjects enrolled | Austria: 3             |
| Country: Number of subjects enrolled | Brazil: 8              |
| Country: Number of subjects enrolled | China: 63              |
| Country: Number of subjects enrolled | Czechia: 18            |
| Country: Number of subjects enrolled | France: 3              |
| Country: Number of subjects enrolled | Germany: 9             |
| Country: Number of subjects enrolled | Hong Kong: 8           |
| Country: Number of subjects enrolled | Hungary: 15            |
| Country: Number of subjects enrolled | Israel: 15             |
| Country: Number of subjects enrolled | Italy: 7               |
| Country: Number of subjects enrolled | Japan: 34              |
| Country: Number of subjects enrolled | Korea, Republic of: 48 |
| Country: Number of subjects enrolled | Poland: 47             |
| Country: Number of subjects enrolled | Portugal: 9            |
| Country: Number of subjects enrolled | Russian Federation: 17 |
| Country: Number of subjects enrolled | Singapore: 3           |
| Country: Number of subjects enrolled | Spain: 14              |

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Taiwan: 14         |
| Country: Number of subjects enrolled | United Kingdom: 10 |
| Country: Number of subjects enrolled | United States: 126 |
| Worldwide total number of subjects   | 553                |
| EEA total number of subjects         | 125                |

Notes:

| <b>Subjects enrolled per age group</b>    |     |
|-------------------------------------------|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 277 |
| From 65 to 84 years                       | 262 |
| 85 years and over                         | 14  |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 768 patients were screened; 9 of these patients were rescreened and randomized in the study. A total of 215 patients failed screening due to not meeting the inclusion criteria. A total of 553 patients with BRVO were randomized 1:1 into the study: 276 to the faricimab Q4W arm and 277 to the aflibercept Q4W arm.

### Period 1

|                              |                                               |
|------------------------------|-----------------------------------------------|
| Period 1 title               | Overall Study (overall period)                |
| Is this the baseline period? | Yes                                           |
| Allocation method            | Randomised - controlled                       |
| Blinding used                | Double blind                                  |
| Roles blinded                | Subject, Investigator, Data analyst, Assessor |

### Arms

|                              |                                                       |
|------------------------------|-------------------------------------------------------|
| Are arms mutually exclusive? | Yes                                                   |
| <b>Arm title</b>             | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) |

Arm description:

In Part 1 (Day 1 through Week 24), participants were randomly assigned to Arm A to receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).

|                                        |                        |
|----------------------------------------|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | Faricimab              |
| Investigational medicinal product code | RO6867461              |
| Other name                             | VABYSMO®               |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intravitreal use       |

Dosage and administration details:

Patients randomly assigned to Arm A received 6 mg faricimab intravitreal injections once every 4 weeks (Q4W) from Day 1 through Week 20 (6 injections) in Part 1 of the study. In Part 2 of the study, patients in Arm A switched from faricimab Q4W to receive 6 mg faricimab intravitreal injections according to a personalized treatment interval (PTI) dosing regimen from Week 24 through Week 68.

|                  |                                                         |
|------------------|---------------------------------------------------------|
| <b>Arm title</b> | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|------------------|---------------------------------------------------------|

Arm description:

In Part 1 (Day 1 through Week 24), participants were randomly assigned to Arm B to receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was to be administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).

|                                        |                        |
|----------------------------------------|------------------------|
| Arm type                               | Active comparator      |
| Investigational medicinal product name | Faricimab              |
| Investigational medicinal product code | RO6867461              |
| Other name                             | VABYSMO®               |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intravitreal use       |

Dosage and administration details:

In Part 2 of the study, patients in Arm B switched from aflibercept to receive 6 mg faricimab intravitreal

injections according to a personalized treatment interval (PTI) dosing regimen from Week 24 through Week 68.

|                                        |                        |
|----------------------------------------|------------------------|
| Investigational medicinal product name | Aflibercept            |
| Investigational medicinal product code |                        |
| Other name                             | Eylea                  |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intravitreal use       |

Dosage and administration details:

Patients randomly assigned to Arm B received 2 mg aflibercept intravitreal injections once every 4 weeks (Q4W) from Day 1 through Week 20 (6 injections) in Part 1 of the study.

| <b>Number of subjects in period 1</b>              | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|----------------------------------------------------|-------------------------------------------------------|---------------------------------------------------------|
| Started                                            | 276                                                   | 277                                                     |
| Received ≥1 Dose of Study Drug (Part 1)            | 276                                                   | 274                                                     |
| Completed Part 1                                   | 272                                                   | 274                                                     |
| Started Part 2                                     | 272                                                   | 274                                                     |
| Completed                                          | 245                                                   | 244                                                     |
| Not completed                                      | 31                                                    | 33                                                      |
| Adverse event, serious fatal                       | 2                                                     | 2                                                       |
| Consent withdrawn by subject                       | 14                                                    | 12                                                      |
| Physician decision                                 | -                                                     | 4                                                       |
| Adverse event, non-fatal                           | 1                                                     | 4                                                       |
| Did Not Return to Hospital Due to COVID19 Epidemic | 1                                                     | -                                                       |
| Non-Compliance With Study Drug                     | 2                                                     | 1                                                       |
| Lost to follow-up                                  | 9                                                     | 6                                                       |
| Patient Refused to Continue Study                  | 1                                                     | -                                                       |
| Patient Missed Week 72 Visit Due to SAE            | 1                                                     | 1                                                       |
| Protocol deviation                                 | -                                                     | 3                                                       |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)   |
| Reporting group description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |
| In Part 1 (Day 1 through Week 24), participants were randomly assigned to Arm A to receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).         |                                                         |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
| Reporting group description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |
| In Part 1 (Day 1 through Week 24), participants were randomly assigned to Arm B to receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was to be administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen). |                                                         |

| Reporting group values                             | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|----------------------------------------------------|-------------------------------------------------------|---------------------------------------------------------|-------|
| Number of subjects                                 | 276                                                   | 277                                                     | 553   |
| Age categorical                                    |                                                       |                                                         |       |
| Units: Subjects                                    |                                                       |                                                         |       |
| In utero                                           | 0                                                     | 0                                                       | 0     |
| Preterm newborn infants (gestational age < 37 wks) | 0                                                     | 0                                                       | 0     |
| Newborns (0-27 days)                               | 0                                                     | 0                                                       | 0     |
| Infants and toddlers (28 days-23 months)           | 0                                                     | 0                                                       | 0     |
| Children (2-11 years)                              | 0                                                     | 0                                                       | 0     |
| Adolescents (12-17 years)                          | 0                                                     | 0                                                       | 0     |
| Adults (18-64 years)                               | 133                                                   | 144                                                     | 277   |
| From 65-84 years                                   | 133                                                   | 129                                                     | 262   |
| 85 years and over                                  | 10                                                    | 4                                                       | 14    |
| Age Continuous                                     |                                                       |                                                         |       |
| Units: Years                                       |                                                       |                                                         |       |
| arithmetic mean                                    | 64.3                                                  | 63.8                                                    |       |
| standard deviation                                 | ± 10.7                                                | ± 10.6                                                  | -     |
| Sex: Female, Male                                  |                                                       |                                                         |       |
| Units: Participants                                |                                                       |                                                         |       |
| Female                                             | 133                                                   | 147                                                     | 280   |
| Male                                               | 143                                                   | 130                                                     | 273   |
| Race (NIH/OMB)                                     |                                                       |                                                         |       |
| Units: Subjects                                    |                                                       |                                                         |       |
| American Indian or Alaska Native                   | 3                                                     | 0                                                       | 3     |
| Asian                                              | 90                                                    | 94                                                      | 184   |
| Native Hawaiian or Other Pacific Islander          | 1                                                     | 0                                                       | 1     |
| Black or African American                          | 6                                                     | 7                                                       | 13    |
| White                                              | 172                                                   | 172                                                     | 344   |

|                                                                             |         |         |     |
|-----------------------------------------------------------------------------|---------|---------|-----|
| More than one race                                                          | 0       | 0       | 0   |
| Unknown or Not Reported                                                     | 4       | 4       | 8   |
| Ethnicity (NIH/OMB)                                                         |         |         |     |
| Units: Subjects                                                             |         |         |     |
| Hispanic or Latino                                                          | 47      | 51      | 98  |
| Not Hispanic or Latino                                                      | 224     | 224     | 448 |
| Unknown or Not Reported                                                     | 5       | 2       | 7   |
| Region of Enrollment                                                        |         |         |     |
| Units: Subjects                                                             |         |         |     |
| Rest of the World                                                           | 129     | 128     | 257 |
| Asia                                                                        | 85      | 85      | 170 |
| USA and Canada                                                              | 62      | 64      | 126 |
| Number of Participants by the Eye (Left or Right) Chosen as the Study Eye   |         |         |     |
| Units: Subjects                                                             |         |         |     |
| Left Eye                                                                    | 140     | 127     | 267 |
| Right Eye                                                                   | 136     | 150     | 286 |
| Number of Participants by the BCVA Letter Score Categories in the Study Eye |         |         |     |
| Units: Subjects                                                             |         |         |     |
| ≤54 Letters (20/80 or Worse)                                                | 89      | 90      | 179 |
| ≥55 Letters (20/80 or Better)                                               | 187     | 187     | 374 |
| Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye           |         |         |     |
| Units: ETDRS Letters                                                        |         |         |     |
| arithmetic mean                                                             | 57.50   | 57.64   |     |
| standard deviation                                                          | ± 13.04 | ± 12.15 | -   |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)   |
| Reporting group description:<br>In Part 1 (Day 1 through Week 24), participants were randomly assigned to Arm A to receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).         |                                                         |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
| Reporting group description:<br>In Part 1 (Day 1 through Week 24), participants were randomly assigned to Arm B to receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was to be administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen). |                                                         |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Arm A: Faricimab Q4W (Part 1)                           |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Intention-to-treat                                      |
| Subject analysis set description:<br>In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A were to receive faricimab 6 milligrams (mg) administered by intravitreal (IVT) injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).                                                                                                                                                                                                                                                                                                                      |                                                         |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Arm B: Aflibercept Q4W (Part 1)                         |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Intention-to-treat                                      |
| Subject analysis set description:<br>In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B were to receive aflibercept 2 milligrams (mg) administered by intravitreal (IVT) injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).                                                                                                                                                                                                                                                                                                                    |                                                         |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Arm A: Faricimab Q4W to Faricimab PTI (Part 2)          |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Intention-to-treat                                      |
| Subject analysis set description:<br>In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).                                                                                                                                                                                                                           |                                                         |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)        |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Intention-to-treat                                      |
| Subject analysis set description:<br>In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was to be administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).                                                                                                                                                                                                                     |                                                         |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Arm A: Faricimab Q4W to Faricimab PTI (Part 2)          |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Intention-to-treat                                      |
| Subject analysis set description:<br>In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).                                                                                                                                                                                                                           |                                                         |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)        |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Intention-to-treat                                      |
| Subject analysis set description:<br>In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was to be administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).                                                                                                                                                                                                                     |                                                         |



(according to the PTI dosing regimen).

|                            |                                 |
|----------------------------|---------------------------------|
| Subject analysis set title | Arm B: Aflibercept Q4W (Part 1) |
| Subject analysis set type  | Safety analysis                 |

Subject analysis set description:

In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B were to receive aflibercept 2 milligrams (mg) administered by intravitreal (IVT) injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).

|                            |                                                |
|----------------------------|------------------------------------------------|
| Subject analysis set title | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) |
| Subject analysis set type  | Safety analysis                                |

Subject analysis set description:

In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).

|                            |                                                  |
|----------------------------|--------------------------------------------------|
| Subject analysis set title | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
| Subject analysis set type  | Safety analysis                                  |

Subject analysis set description:

In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was to be administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).

|                            |                            |
|----------------------------|----------------------------|
| Subject analysis set title | All Faricimab Participants |
| Subject analysis set type  | Safety analysis            |

Subject analysis set description:

This immunogenicity analysis group represents all participants with an evaluable ADA sample. At baseline, evaluable participants were those with an ADA sample prior to faricimab injection, including those who did not receive study treatment; post-baseline, evaluable participants were those with an ADA sample after having received at least one dose of faricimab.

### **Primary: Part 1: Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24**

|                 |                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------------|
| End point title | Part 1: Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 |
|-----------------|-------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From Baseline through Week 24

| End point values                          | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-------------------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                        | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed               | 276                                 | 277                                   |  |  |
| Units: ETDRS Letters                      |                                     |                                       |  |  |
| arithmetic mean (confidence interval 95%) | 16.9 (15.7 to 18.1)                 | 17.5 (16.3 to 18.6)                   |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                            | BCVA Non-inferiority                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                     |                                                                 |
| The null hypothesis, $H_0: \mu(\text{faricimab}) - \mu(\text{afibercept}) \leq -4$ letters; the alternative hypothesis, $H_a: \mu(\text{faricimab}) - \mu(\text{afibercept}) > -4$ letters. The final sample size provided >90% power for the non-inferiority assessment (at a one-sided 0.02485 significance level). |                                                                 |
| Comparison groups                                                                                                                                                                                                                                                                                                     | Arm A: Faricimab Q4W (Part 1) v Arm B: Aflibercept Q4W (Part 1) |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                               | 553                                                             |
| Analysis specification                                                                                                                                                                                                                                                                                                | Pre-specified                                                   |
| Analysis type                                                                                                                                                                                                                                                                                                         | non-inferiority <sup>[1]</sup>                                  |
| Parameter estimate                                                                                                                                                                                                                                                                                                    | Difference in Adjusted Means                                    |
| Point estimate                                                                                                                                                                                                                                                                                                        | -0.6                                                            |
| Confidence interval                                                                                                                                                                                                                                                                                                   |                                                                 |
| level                                                                                                                                                                                                                                                                                                                 | 95 %                                                            |
| sides                                                                                                                                                                                                                                                                                                                 | 2-sided                                                         |
| lower limit                                                                                                                                                                                                                                                                                                           | -2.2                                                            |
| upper limit                                                                                                                                                                                                                                                                                                           | 1.1                                                             |
| Variability estimate                                                                                                                                                                                                                                                                                                  | Standard error of the mean                                      |
| Dispersion value                                                                                                                                                                                                                                                                                                      | 0.84                                                            |

Notes:

[1] - If the lower bound of a two-sided 95% confidence interval (CI) for the difference in adjusted means of the two treatments (faricimab minus aflibercept) is greater than -4 letters (the non-inferiority margin), then faricimab is considered non-inferior to aflibercept.

| Statistical analysis title                                                                                       | BCVA Superiority                                                |
|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Statistical analysis description:                                                                                |                                                                 |
| The final sample size provided >80% power for a 3.5-letter superiority assessment of faricimab over aflibercept. |                                                                 |
| Comparison groups                                                                                                | Arm A: Faricimab Q4W (Part 1) v Arm B: Aflibercept Q4W (Part 1) |
| Number of subjects included in analysis                                                                          | 553                                                             |
| Analysis specification                                                                                           | Pre-specified                                                   |
| Analysis type                                                                                                    | superiority                                                     |
| P-value                                                                                                          | = 0.4978 <sup>[2]</sup>                                         |
| Method                                                                                                           | Mixed Model of Repeated Measures                                |
| Parameter estimate                                                                                               | Difference in Adjusted Means                                    |
| Point estimate                                                                                                   | -0.6                                                            |
| Confidence interval                                                                                              |                                                                 |
| level                                                                                                            | 95 %                                                            |
| sides                                                                                                            | 2-sided                                                         |
| lower limit                                                                                                      | -2.2                                                            |
| upper limit                                                                                                      | 1.1                                                             |
| Variability estimate                                                                                             | Standard error of the mean                                      |
| Dispersion value                                                                                                 | 0.84                                                            |

Notes:

[2] - Tested at a two-sided 0.0497 significance level.

## Secondary: Part 1: Change from Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------|
| End point title | Part 1: Change from Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|-----------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                          | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-------------------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                        | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed               | 276                                 | 277                                   |  |  |
| Units: ETDRS Letters                      |                                     |                                       |  |  |
| arithmetic mean (confidence interval 95%) |                                     |                                       |  |  |
| Week 4                                    | 11.5 (10.5 to 12.5)                 | 12.4 (11.4 to 13.4)                   |  |  |
| Week 8                                    | 13.7 (12.6 to 14.7)                 | 15.1 (14.1 to 16.2)                   |  |  |
| Week 12                                   | 15.1 (14.0 to 16.2)                 | 15.9 (14.8 to 17.0)                   |  |  |
| Week 16                                   | 15.5 (14.4 to 16.6)                 | 16.5 (15.4 to 17.7)                   |  |  |
| Week 20                                   | 16.3 (15.2 to 17.4)                 | 17.3 (16.1 to 18.4)                   |  |  |
| Week 24                                   | 16.9 (15.7 to 18.1)                 | 17.5 (16.3 to 18.6)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Percentage of Participants Gaining $\geq 15$ Letters in BCVA from Baseline in the Study Eye at Week 24

|                 |                                                                                                                |
|-----------------|----------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Gaining $\geq 15$ Letters in BCVA from Baseline in the Study Eye at Week 24 |
|-----------------|----------------------------------------------------------------------------------------------------------------|

**End point description:**

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Baseline and Week 24 |           |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  | 56.1 (50.4 to 61.9)                 | 60.4 (54.7 to 66.0)                   |  |  |

**Statistical analyses**

|                                         |                                                                 |
|-----------------------------------------|-----------------------------------------------------------------|
| <b>Statistical analysis title</b>       | Gaining $\geq 15$ Letters                                       |
| Comparison groups                       | Arm A: Faricimab Q4W (Part 1) v Arm B: Aflibercept Q4W (Part 1) |
| Number of subjects included in analysis | 553                                                             |
| Analysis specification                  | Pre-specified                                                   |
| Analysis type                           | other                                                           |
| Parameter estimate                      | Difference in CMH Weighted Percentage                           |
| Point estimate                          | -4.3                                                            |
| Confidence interval                     |                                                                 |
| level                                   | 95 %                                                            |
| sides                                   | 2-sided                                                         |
| lower limit                             | -12.3                                                           |
| upper limit                             | 3.8                                                             |

**Secondary: Part 1: Percentage of Participants Gaining  $\geq 15$  Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24**

|                 |                                                                                                                                             |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Gaining $\geq 15$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|

**End point description:**

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights

stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                                          |           |
|------------------------------------------|-----------|
| End point type                           | Secondary |
| End point timeframe:                     |           |
| Baseline, Weeks 4, 8, 12, 16, 20, and 24 |           |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 34.3 (28.9 to 39.8)                 | 36.9 (31.5 to 42.3)                   |  |  |
| Week 8                            | 41.2 (35.6 to 46.9)                 | 46.7 (41.0 to 52.3)                   |  |  |
| Week 12                           | 51.0 (45.3 to 56.7)                 | 52.1 (46.3 to 57.8)                   |  |  |
| Week 16                           | 53.6 (47.8 to 59.3)                 | 56.4 (50.8 to 62.1)                   |  |  |
| Week 20                           | 56.1 (50.3 to 61.8)                 | 58.9 (53.3 to 64.6)                   |  |  |
| Week 24                           | 56.1 (50.4 to 61.9)                 | 60.4 (54.7 to 66.0)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Percentage of Participants Gaining $\geq 10$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                             |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Gaining $\geq 10$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                                          |           |
|------------------------------------------|-----------|
| End point type                           | Secondary |
| End point timeframe:                     |           |
| Baseline, Weeks 4, 8, 12, 16, 20, and 24 |           |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 57.5 (51.8 to 63.3)                 | 59.2 (53.6 to 64.9)                   |  |  |
| Week 8                            | 69.1 (63.8 to 74.5)                 | 69.0 (63.6 to 74.4)                   |  |  |
| Week 12                           | 75.0 (69.9 to 80.1)                 | 74.8 (69.7 to 79.8)                   |  |  |
| Week 16                           | 72.1 (66.9 to 77.3)                 | 76.6 (71.6 to 81.5)                   |  |  |
| Week 20                           | 75.3 (70.3 to 80.4)                 | 79.1 (74.3 to 83.9)                   |  |  |
| Week 24                           | 77.5 (72.6 to 82.4)                 | 77.3 (72.4 to 82.2)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Percentage of Participants Gaining $\geq 5$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                            |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Gaining $\geq 5$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 75.7 (70.7 to 80.7)                 | 79.1 (74.4 to 83.9)                   |  |  |
| Week 8                            | 84.0 (79.7 to 88.3)                 | 88.1 (84.3 to 91.9)                   |  |  |
| Week 12                           | 87.0 (83.1 to 90.9)                 | 87.0 (83.1 to 91.0)                   |  |  |
| Week 16                           | 85.9 (81.8 to 89.9)                 | 88.8 (85.1 to 92.5)                   |  |  |
| Week 20                           | 88.4 (84.6 to 92.2)                 | 90.3 (86.8 to 93.7)                   |  |  |
| Week 24                           | 90.9 (87.6 to 94.3)                 | 89.6 (86.0 to 93.1)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1: Percentage of Participants Gaining >0 Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                      |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Gaining >0 Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 90.2 (86.8 to 93.6)                 | 93.2 (90.3 to 96.1)                   |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 8  | 92.7 (89.7 to 95.8) | 96.8 (94.7 to 98.8) |  |  |
| Week 12 | 94.9 (92.4 to 97.5) | 94.2 (91.5 to 97.0) |  |  |
| Week 16 | 93.8 (91.1 to 96.6) | 94.9 (92.4 to 97.5) |  |  |
| Week 20 | 94.9 (92.4 to 97.5) | 96.0 (93.8 to 98.3) |  |  |
| Week 24 | 96.4 (94.2 to 98.6) | 95.3 (92.9 to 97.8) |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1: Percentage of Participants Avoiding a Loss of $\geq 15$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                                        |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Avoiding a Loss of $\geq 15$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 99.3 (98.3 to 100.0)                | 98.9 (97.7 to 100.0)                  |  |  |
| Week 8                            | 99.3 (98.3 to 100.0)                | 98.9 (97.7 to 100.0)                  |  |  |
| Week 12                           | 99.3 (98.3 to 100.0)                | 98.9 (97.7 to 100.0)                  |  |  |
| Week 16                           | 99.3 (98.3 to 100.0)                | 98.6 (97.2 to 99.9)                   |  |  |
| Week 20                           | 99.6 (98.9 to 100.0)                | 98.6 (97.2 to 99.9)                   |  |  |
| Week 24                           | 99.6 (98.9 to 100.0)                | 98.6 (97.2 to 99.9)                   |  |  |



## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1: Percentage of Participants Avoiding a Loss of $\geq 10$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                                        |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Avoiding a Loss of $\geq 10$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

#### End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

#### End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 98.5 (97.1 to 99.9)                 | 98.9 (97.7 to 100.0)                  |  |  |
| Week 8                            | 98.5 (97.1 to 100.0)                | 98.9 (97.7 to 100.0)                  |  |  |
| Week 12                           | 98.5 (97.1 to 99.9)                 | 98.9 (97.7 to 100.0)                  |  |  |
| Week 16                           | 98.5 (97.1 to 99.9)                 | 98.2 (96.7 to 99.7)                   |  |  |
| Week 20                           | 99.3 (98.3 to 100.0)                | 98.6 (97.2 to 99.9)                   |  |  |
| Week 24                           | 99.6 (98.9 to 100.0)                | 98.2 (96.7 to 99.7)                   |  |  |

## Statistical analyses

**Secondary: Part 1: Percentage of Participants Avoiding a Loss of  $\geq 5$  Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24**

|                 |                                                                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Avoiding a Loss of $\geq 5$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

## End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 97.1 (95.1 to 99.1)                 | 98.6 (97.2 to 99.9)                   |  |  |
| Week 8                            | 97.8 (96.1 to 99.5)                 | 98.6 (97.2 to 99.9)                   |  |  |
| Week 12                           | 97.8 (96.1 to 99.5)                 | 98.9 (97.7 to 100.0)                  |  |  |
| Week 16                           | 97.8 (96.1 to 99.5)                 | 98.2 (96.7 to 99.7)                   |  |  |
| Week 20                           | 98.5 (97.1 to 99.9)                 | 97.8 (96.2 to 99.5)                   |  |  |
| Week 24                           | 98.6 (97.2 to 100.0)                | 97.5 (95.7 to 99.3)                   |  |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Part 1: Percentage of Participants Achieving  $\geq 84$  Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24**

|                 |                                                                                                                                                            |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Achieving $\geq 84$ Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

## End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study

(ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                                          |           |
|------------------------------------------|-----------|
| End point type                           | Secondary |
| End point timeframe:                     |           |
| Baseline, Weeks 4, 8, 12, 16, 20, and 24 |           |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 8.7 (5.5 to 11.9)                   | 8.6 (5.5 to 11.8)                     |  |  |
| Week 8                            | 14.1 (10.3 to 18.0)                 | 15.5 (11.5 to 19.5)                   |  |  |
| Week 12                           | 15.6 (11.7 to 19.6)                 | 20.2 (15.7 to 24.6)                   |  |  |
| Week 16                           | 17.4 (13.3 to 21.6)                 | 22.0 (17.4 to 26.5)                   |  |  |
| Week 20                           | 20.7 (16.2 to 25.2)                 | 23.8 (19.0 to 28.5)                   |  |  |
| Week 24                           | 22.9 (18.2 to 27.6)                 | 23.8 (19.1 to 28.5)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Percentage of Participants Achieving $\geq 69$ Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                                                      |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants Achieving $\geq 69$ Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 55.6 (50.6 to 60.5)                 | 62.3 (57.3 to 67.3)                   |  |  |
| Week 8                            | 63.9 (59.3 to 68.6)                 | 70.3 (65.7 to 74.9)                   |  |  |
| Week 12                           | 69.0 (64.4 to 73.6)                 | 69.2 (64.4 to 74.0)                   |  |  |
| Week 16                           | 72.2 (67.7 to 76.8)                 | 72.1 (67.5 to 76.8)                   |  |  |
| Week 20                           | 73.3 (69.1 to 77.6)                 | 76.1 (71.7 to 80.5)                   |  |  |
| Week 24                           | 73.7 (69.3 to 78.1)                 | 76.5 (71.9 to 81.0)                   |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1: Percentage of Participants with $\leq 38$ Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                                                 |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants with $\leq 38$ Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA ( $>38$  and  $\leq 38$  letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 3.6 (2.0 to 5.3)                    | 1.5 (0.1 to 2.9)                      |  |  |
| Week 8                            | 3.2 (1.3 to 5.0)                    | 1.9 (0.5 to 3.3)                      |  |  |
| Week 12                           | 2.3 (0.8 to 3.8)                    | 1.5 (0.2 to 2.8)                      |  |  |
| Week 16                           | 2.3 (0.8 to 3.8)                    | 1.9 (0.4 to 3.3)                      |  |  |
| Week 20                           | 2.3 (0.8 to 3.8)                    | 1.9 (0.4 to 3.3)                      |  |  |
| Week 24                           | 2.3 (0.8 to 3.8)                    | 1.9 (0.4 to 3.3)                      |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Change from Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                     |
|-----------------|---------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Change from Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|---------------------------------------------------------------------------------------------------------------------|

End point description:

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                          | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-------------------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                        | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed               | 276                                 | 277                                   |  |  |
| Units: microns                            |                                     |                                       |  |  |
| arithmetic mean (confidence interval 95%) |                                     |                                       |  |  |
| Week 4                                    | -283.9 (-290.1 to -277.8)           | -281.1 (-287.2 to -274.9)             |  |  |
| Week 8                                    | -299.4 (-305.2 to -293.7)           | -296.9 (-302.6 to -291.2)             |  |  |
| Week 12                                   | -304.4 (-309.7 to -299.1)           | -298.8 (-304.1 to -293.5)             |  |  |

|         |                           |                           |  |  |
|---------|---------------------------|---------------------------|--|--|
| Week 16 | -306.1 (-311.5 to -300.8) | -301.4 (-306.7 to -296.1) |  |  |
| Week 20 | -307.3 (-312.5 to -302.1) | -302.2 (-307.4 to -297.0) |  |  |
| Week 24 | -311.4 (-316.4 to -306.4) | -304.4 (-309.3 to -299.4) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Percentage of Participants with Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                           |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants with Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|

End point description:

Absence of diabetic macular edema was defined as achieving a central subfield thickness of <325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 88.8 (85.1 to 92.5)                 | 88.1 (84.4 to 91.9)                   |  |  |
| Week 8                            | 94.5 (91.9 to 97.2)                 | 93.2 (90.3 to 96.1)                   |  |  |
| Week 12                           | 96.4 (94.2 to 98.5)                 | 92.1 (89.0 to 95.2)                   |  |  |
| Week 16                           | 95.3 (92.8 to 97.7)                 | 93.6 (90.7 to 96.4)                   |  |  |
| Week 20                           | 96.0 (93.7 to 98.3)                 | 94.6 (92.1 to 97.2)                   |  |  |
| Week 24                           | 95.3 (92.8 to 97.7)                 | 93.9 (91.2 to 96.6)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1: Percentage of Participants with Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants with Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------|

End point description:

Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, and 24

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 46.1 (40.2 to 51.9)                 | 54.8 (49.0 to 60.6)                   |  |  |
| Week 8                            | 53.8 (48.2 to 59.4)                 | 57.4 (51.6 to 63.1)                   |  |  |
| Week 12                           | 65.3 (59.7 to 70.8)                 | 56.6 (50.8 to 62.4)                   |  |  |
| Week 16                           | 69.9 (64.6 to 75.3)                 | 72.9 (67.8 to 78.1)                   |  |  |
| Week 20                           | 67.1 (61.6 to 72.6)                 | 66.4 (60.9 to 71.9)                   |  |  |
| Week 24                           | 72.5 (67.3 to 77.7)                 | 66.0 (60.5 to 71.6)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1: Percentage of Participants with Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                              |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants with Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|

End point description:

Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was

estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                                          |           |
|------------------------------------------|-----------|
| End point type                           | Secondary |
| End point timeframe:                     |           |
| Baseline, Weeks 4, 8, 12, 16, 20, and 24 |           |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 76.1 (71.1 to 81.1)                 | 72.9 (67.8 to 78.1)                   |  |  |
| Week 8                            | 93.1 (90.2 to 96.1)                 | 91.4 (88.1 to 94.6)                   |  |  |
| Week 12                           | 96.4 (94.2 to 98.6)                 | 97.1 (95.2 to 99.1)                   |  |  |
| Week 16                           | 95.3 (92.8 to 97.8)                 | 96.4 (94.2 to 98.6)                   |  |  |
| Week 20                           | 98.2 (96.6 to 99.8)                 | 97.8 (96.1 to 99.5)                   |  |  |
| Week 24                           | 91.3 (88.0 to 94.6)                 | 90.3 (86.9 to 93.7)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Percentage of Participants with Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

|                 |                                                                                                                                                     |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Percentage of Participants with Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                                          |           |
|------------------------------------------|-----------|
| End point type                           | Secondary |
| End point timeframe:                     |           |
| Baseline, Weeks 4, 8, 12, 16, 20, and 24 |           |



| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-----------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed       | 276                                 | 277                                   |  |  |
| Units: Percentage of participants |                                     |                                       |  |  |
| number (confidence interval 95%)  |                                     |                                       |  |  |
| Week 4                            | 37.8 (32.1 to 43.4)                 | 40.8 (35.2 to 46.4)                   |  |  |
| Week 8                            | 50.9 (45.3 to 56.5)                 | 54.1 (48.4 to 59.9)                   |  |  |
| Week 12                           | 63.8 (58.2 to 69.4)                 | 56.3 (50.5 to 62.1)                   |  |  |
| Week 16                           | 67.1 (61.6 to 72.6)                 | 72.6 (67.4 to 77.8)                   |  |  |
| Week 20                           | 66.0 (60.5 to 71.5)                 | 66.0 (60.5 to 71.6)                   |  |  |
| Week 24                           | 66.3 (60.8 to 71.9)                 | 61.0 (55.3 to 66.7)                   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Change from Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24

|                 |                                                                                                                                         |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 1: Change from Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24 |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the ANCOVA analysis, the model uses the non-missing change from baseline in BCVA at Weeks 24 as the response variables adjusted for the treatment group, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA score ( $\geq 55$  and  $\leq 54$  letters) and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were not imputed. 95% CI is a rounding of 95.03% CI.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Baseline and Week 24 |           |

| End point values                          | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) |  |  |
|-------------------------------------------|-------------------------------------|---------------------------------------|--|--|
| Subject group type                        | Subject analysis set                | Subject analysis set                  |  |  |
| Number of subjects analysed               | 253                                 | 244                                   |  |  |
| Units: score on a scale                   |                                     |                                       |  |  |
| arithmetic mean (confidence interval 95%) | 5.6 (4.5 to 6.7)                    | 5.9 (4.8 to 7.1)                      |  |  |

## Statistical analyses

| Statistical analysis title              | NEI VFQ-25 at Week 24                                           |
|-----------------------------------------|-----------------------------------------------------------------|
| Comparison groups                       | Arm A: Faricimab Q4W (Part 1) v Arm B: Aflibercept Q4W (Part 1) |
| Number of subjects included in analysis | 497                                                             |
| Analysis specification                  | Pre-specified                                                   |
| Analysis type                           | other                                                           |
| Parameter estimate                      | Difference in Adjusted Means                                    |
| Point estimate                          | -0.4                                                            |
| Confidence interval                     |                                                                 |
| level                                   | 95 %                                                            |
| sides                                   | 2-sided                                                         |
| lower limit                             | -1.9                                                            |
| upper limit                             | 1.1                                                             |
| Variability estimate                    | Standard error of the mean                                      |
| Dispersion value                        | 0.76                                                            |

## Secondary: Parts 1 and 2: Change from Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72

|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title        | Parts 1 and 2: Change from Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| End point description: | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors [baseline BCVA ( $\geq 55$ and $\leq 54$ letters), and region (U.S. and Canada, Asia, and rest of the world)] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI. |
| End point type         | Secondary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| End point timeframe:   | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

| End point values                          | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                        | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed               | 276                                                               | 277                                                                 |  |  |
| Units: ETDRS Letters                      |                                                                   |                                                                     |  |  |
| arithmetic mean (confidence interval 95%) |                                                                   |                                                                     |  |  |
| Week 4                                    | 11.5 (10.5 to 12.5)                                               | 12.4 (11.4 to 13.4)                                                 |  |  |
| Week 8                                    | 13.7 (12.6 to 14.7)                                               | 15.1 (14.1 to 16.2)                                                 |  |  |
| Week 12                                   | 15.1 (14.0 to 16.1)                                               | 15.9 (14.8 to 17.0)                                                 |  |  |
| Week 16                                   | 15.5 (14.4 to 16.6)                                               | 16.5 (15.4 to 17.6)                                                 |  |  |
| Week 20                                   | 16.3 (15.1 to 17.4)                                               | 17.2 (16.1 to 18.4)                                                 |  |  |
| Week 24                                   | 16.8 (15.6 to 17.9)                                               | 17.5 (16.3 to 18.6)                                                 |  |  |
| Week 28                                   | 16.5 (15.3 to 17.6)                                               | 17.3 (16.2 to 18.4)                                                 |  |  |
| Week 32                                   | 17.2 (16.0 to 18.4)                                               | 17.5 (16.3 to 18.7)                                                 |  |  |
| Week 36                                   | 17.3 (16.1 to 18.4)                                               | 18.0 (16.8 to 19.2)                                                 |  |  |
| Week 40                                   | 17.3 (16.1 to 18.4)                                               | 17.7 (16.6 to 18.9)                                                 |  |  |
| Week 44                                   | 18.1 (16.8 to 19.3)                                               | 17.7 (16.5 to 18.9)                                                 |  |  |
| Week 48                                   | 18.0 (16.8 to 19.3)                                               | 18.2 (17.0 to 19.4)                                                 |  |  |
| Week 52                                   | 18.0 (16.7 to 19.3)                                               | 18.4 (17.1 to 19.7)                                                 |  |  |
| Week 56                                   | 17.3 (16.0 to 18.6)                                               | 18.1 (16.8 to 19.4)                                                 |  |  |
| Week 60                                   | 18.0 (16.7 to 19.3)                                               | 18.6 (17.3 to 19.8)                                                 |  |  |
| Week 64                                   | 17.9 (16.6 to 19.2)                                               | 18.6 (17.3 to 19.9)                                                 |  |  |
| Week 68                                   | 18.1 (16.8 to 19.4)                                               | 18.8 (17.5 to 20.1)                                                 |  |  |
| Week 72                                   | 18.4 (17.1 to 19.7)                                               | 18.8 (17.5 to 20.1)                                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants Gaining ≥15 Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                              |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants Gaining ≥15 Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 34.3 (28.9 to 39.8)                                               | 36.9 (31.5 to 42.3)                                                 |  |  |
| Week 8                            | 41.2 (35.6 to 46.9)                                               | 46.7 (41.0 to 52.3)                                                 |  |  |
| Week 12                           | 51.0 (45.3 to 56.7)                                               | 52.1 (46.3 to 57.8)                                                 |  |  |
| Week 16                           | 53.6 (47.8 to 59.3)                                               | 56.4 (50.8 to 62.1)                                                 |  |  |
| Week 20                           | 56.1 (50.3 to 61.8)                                               | 58.9 (53.3 to 64.6)                                                 |  |  |
| Week 24                           | 56.1 (50.4 to 61.9)                                               | 60.4 (54.7 to 66.0)                                                 |  |  |
| Week 28                           | 55.8 (50.0 to 61.5)                                               | 61.8 (56.2 to 67.4)                                                 |  |  |
| Week 32                           | 59.0 (53.3 to 64.6)                                               | 61.4 (55.8 to 67.1)                                                 |  |  |
| Week 36                           | 61.2 (55.5 to 66.8)                                               | 62.5 (56.9 to 68.1)                                                 |  |  |
| Week 40                           | 60.8 (55.2 to 66.4)                                               | 61.1 (55.4 to 66.7)                                                 |  |  |
| Week 44                           | 65.5 (60.1 to 71.0)                                               | 58.9 (53.4 to 64.5)                                                 |  |  |
| Week 48                           | 64.1 (58.5 to 69.6)                                               | 60.7 (55.1 to 66.3)                                                 |  |  |
| Week 52                           | 61.2 (55.6 to 66.8)                                               | 64.0 (58.4 to 69.5)                                                 |  |  |
| Week 56                           | 57.9 (52.3 to 63.5)                                               | 63.6 (58.1 to 69.2)                                                 |  |  |
| Week 60                           | 62.6 (57.1 to 68.1)                                               | 62.9 (57.4 to 68.4)                                                 |  |  |
| Week 64                           | 61.9 (56.3 to 67.4)                                               | 65.4 (59.9 to 70.9)                                                 |  |  |
| Week 68                           | 63.0 (57.5 to 68.4)                                               | 64.7 (59.2 to 70.2)                                                 |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 72 | 62.3 (56.7 to 67.8) | 66.9 (61.5 to 72.3) |  |  |
|---------|---------------------|---------------------|--|--|

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants Gaining $\geq 10$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Parts 1 and 2: Percentage of Participants Gaining $\geq 10$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                    |
| Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$ and $\leq 54$ letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI. |                                                                                                                                                    |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Secondary                                                                                                                                          |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                    |
| Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                    |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 57.5 (51.8 to 63.3)                                               | 59.2 (53.6 to 64.9)                                                 |  |  |
| Week 8                            | 69.1 (63.8 to 74.5)                                               | 69.0 (63.6 to 74.4)                                                 |  |  |
| Week 12                           | 75.0 (69.9 to 80.1)                                               | 74.8 (69.7 to 79.8)                                                 |  |  |
| Week 16                           | 72.1 (66.9 to 77.3)                                               | 76.6 (71.6 to 81.5)                                                 |  |  |
| Week 20                           | 75.3 (70.3 to 80.4)                                               | 79.1 (74.3 to 83.9)                                                 |  |  |
| Week 24                           | 77.5 (72.6 to 82.4)                                               | 77.3 (72.4 to 82.2)                                                 |  |  |
| Week 28                           | 76.1 (71.1 to 81.1)                                               | 76.6 (71.6 to 81.5)                                                 |  |  |
| Week 32                           | 77.5 (72.6 to 82.4)                                               | 78.4 (73.6 to 83.2)                                                 |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 36 | 75.7 (70.7 to 80.7) | 78.7 (74.0 to 83.5) |  |  |
| Week 40 | 77.5 (72.7 to 82.4) | 76.2 (71.3 to 81.2) |  |  |
| Week 44 | 80.4 (75.8 to 85.1) | 76.6 (71.7 to 81.5) |  |  |
| Week 48 | 79.7 (75.0 to 84.4) | 79.4 (74.7 to 84.2) |  |  |
| Week 52 | 80.8 (76.2 to 85.4) | 80.2 (75.5 to 84.8) |  |  |
| Week 56 | 75.7 (70.7 to 80.7) | 78.0 (73.2 to 82.9) |  |  |
| Week 60 | 79.3 (74.6 to 84.0) | 80.5 (75.9 to 85.2) |  |  |
| Week 64 | 78.9 (74.2 to 83.7) | 78.7 (73.9 to 83.5) |  |  |
| Week 68 | 78.9 (74.2 to 83.7) | 77.3 (72.4 to 82.2) |  |  |
| Week 72 | 80.4 (75.8 to 85.0) | 79.5 (74.7 to 84.2) |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Parts 1 and 2: Percentage of Participants Gaining $\geq 5$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Parts 1 and 2: Percentage of Participants Gaining ≥5 Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                             |
| Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI. |                                                                                                                                             |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary                                                                                                                                   |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                             |
| Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                             |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 4  | 75.7 (70.7 to 80.7) | 79.1 (74.4 to 83.9) |  |  |
| Week 8  | 84.0 (79.7 to 88.3) | 88.1 (84.3 to 91.9) |  |  |
| Week 12 | 87.0 (83.1 to 90.9) | 87.0 (83.1 to 91.0) |  |  |
| Week 16 | 85.9 (81.8 to 89.9) | 88.8 (85.1 to 92.5) |  |  |
| Week 20 | 88.4 (84.6 to 92.2) | 90.3 (86.8 to 93.7) |  |  |
| Week 24 | 90.9 (87.6 to 94.3) | 89.6 (86.0 to 93.1) |  |  |
| Week 28 | 89.1 (85.5 to 92.8) | 87.8 (84.0 to 91.6) |  |  |
| Week 32 | 89.5 (85.9 to 93.1) | 87.7 (83.9 to 91.6) |  |  |
| Week 36 | 88.4 (84.6 to 92.1) | 90.6 (87.2 to 94.0) |  |  |
| Week 40 | 90.2 (86.7 to 93.7) | 90.6 (87.2 to 94.0) |  |  |
| Week 44 | 89.1 (85.5 to 92.8) | 88.4 (84.7 to 92.2) |  |  |
| Week 48 | 88.4 (84.6 to 92.2) | 90.3 (86.8 to 93.8) |  |  |
| Week 52 | 89.9 (86.4 to 93.4) | 88.5 (84.7 to 92.2) |  |  |
| Week 56 | 88.0 (84.3 to 91.8) | 87.0 (83.1 to 91.0) |  |  |
| Week 60 | 89.9 (86.3 to 93.4) | 88.1 (84.3 to 91.9) |  |  |
| Week 64 | 90.6 (87.1 to 94.0) | 87.7 (83.9 to 91.6) |  |  |
| Week 68 | 89.5 (85.9 to 93.1) | 87.1 (83.1 to 91.0) |  |  |
| Week 72 | 89.8 (86.3 to 93.4) | 87.4 (83.5 to 91.3) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                             |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 90.2 (86.8 to 93.6)                                               | 93.2 (90.3 to 96.1)                                                 |  |  |
| Week 8                            | 92.7 (89.7 to 95.8)                                               | 96.8 (94.7 to 98.8)                                                 |  |  |
| Week 12                           | 94.9 (92.4 to 97.5)                                               | 94.2 (91.5 to 97.0)                                                 |  |  |
| Week 16                           | 93.8 (91.1 to 96.6)                                               | 94.9 (92.4 to 97.5)                                                 |  |  |
| Week 20                           | 94.9 (92.4 to 97.5)                                               | 96.0 (93.8 to 98.3)                                                 |  |  |
| Week 24                           | 96.4 (94.2 to 98.6)                                               | 95.3 (92.9 to 97.8)                                                 |  |  |
| Week 28                           | 95.3 (92.9 to 97.8)                                               | 95.0 (92.4 to 97.5)                                                 |  |  |
| Week 32                           | 96.0 (93.8 to 98.3)                                               | 95.0 (92.4 to 97.5)                                                 |  |  |
| Week 36                           | 94.2 (91.5 to 96.9)                                               | 94.6 (92.0 to 97.2)                                                 |  |  |
| Week 40                           | 94.6 (91.9 to 97.2)                                               | 95.7 (93.3 to 98.0)                                                 |  |  |
| Week 44                           | 95.3 (92.9 to 97.7)                                               | 94.6 (92.0 to 97.2)                                                 |  |  |
| Week 48                           | 94.6 (92.0 to 97.2)                                               | 96.1 (93.8 to 98.3)                                                 |  |  |
| Week 52                           | 93.8 (91.1 to 96.6)                                               | 94.6 (92.1 to 97.2)                                                 |  |  |
| Week 56                           | 93.1 (90.2 to 96.1)                                               | 95.3 (92.9 to 97.8)                                                 |  |  |
| Week 60                           | 94.6 (91.9 to 97.2)                                               | 94.2 (91.5 to 97.0)                                                 |  |  |
| Week 64                           | 94.9 (92.4 to 97.5)                                               | 94.2 (91.5 to 97.0)                                                 |  |  |
| Week 68                           | 93.5 (90.6 to 96.4)                                               | 93.9 (91.1 to 96.7)                                                 |  |  |
| Week 72                           | 94.6 (91.9 to 97.2)                                               | 93.9 (91.1 to 96.7)                                                 |  |  |

## Statistical analyses

No statistical analyses for this end point



## Secondary: Parts 1 and 2: Percentage of Participants Avoiding a Loss of $\geq 15$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Parts 1 and 2: Percentage of Participants Avoiding a Loss of $\geq 15$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                               |
| Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$ and $\leq 54$ letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI. |                                                                                                                                                               |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Secondary                                                                                                                                                     |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                               |
| Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                               |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 99.3 (98.3 to 100.0)                                              | 98.9 (97.7 to 100.0)                                                |  |  |
| Week 8                            | 99.3 (98.3 to 100.0)                                              | 98.9 (97.7 to 100.0)                                                |  |  |
| Week 12                           | 99.3 (98.3 to 100.0)                                              | 98.9 (97.7 to 100.0)                                                |  |  |
| Week 16                           | 99.3 (98.3 to 100.0)                                              | 98.6 (97.2 to 99.9)                                                 |  |  |
| Week 20                           | 99.6 (98.9 to 100.0)                                              | 98.6 (97.2 to 99.9)                                                 |  |  |
| Week 24                           | 99.6 (98.9 to 100.0)                                              | 98.6 (97.2 to 99.9)                                                 |  |  |
| Week 28                           | 99.6 (98.9 to 100.0)                                              | 98.6 (97.2 to 99.9)                                                 |  |  |
| Week 32                           | 99.6 (98.9 to 100.0)                                              | 98.6 (97.2 to 99.9)                                                 |  |  |
| Week 36                           | 99.6 (98.9 to 100.0)                                              | 98.6 (97.2 to 100.0)                                                |  |  |
| Week 40                           | 98.9 (97.7 to 100.0)                                              | 98.6 (97.2 to 100.0)                                                |  |  |
| Week 44                           | 99.3 (98.3 to 100.0)                                              | 98.6 (97.2 to 100.0)                                                |  |  |
| Week 48                           | 99.3 (98.3 to 100.0)                                              | 98.2 (96.7 to 99.8)                                                 |  |  |
| Week 52                           | 98.6 (97.2 to 100.0)                                              | 98.2 (96.7 to 99.8)                                                 |  |  |
| Week 56                           | 98.9 (97.7 to 100.0)                                              | 98.2 (96.7 to 99.8)                                                 |  |  |
| Week 60                           | 99.3 (98.3 to 100.0)                                              | 98.2 (96.7 to 99.8)                                                 |  |  |

|         |                      |                     |  |  |
|---------|----------------------|---------------------|--|--|
| Week 64 | 98.9 (97.7 to 100.0) | 97.9 (96.2 to 99.5) |  |  |
| Week 68 | 98.9 (97.7 to 100.0) | 98.2 (96.7 to 99.8) |  |  |
| Week 72 | 98.9 (97.7 to 100.0) | 98.2 (96.7 to 99.8) |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Parts 1 and 2: Percentage of Participants Avoiding a Loss of $\geq 10$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                                               |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants Avoiding a Loss of $\geq 10$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 98.5 (97.1 to 99.9)                                               | 98.9 (97.7 to 100.0)                                                |  |  |
| Week 8                            | 98.5 (97.1 to 100.0)                                              | 98.9 (97.7 to 100.0)                                                |  |  |
| Week 12                           | 98.5 (97.1 to 99.9)                                               | 98.9 (97.7 to 100.0)                                                |  |  |
| Week 16                           | 98.5 (97.1 to 99.9)                                               | 98.2 (96.7 to 99.7)                                                 |  |  |
| Week 20                           | 99.3 (98.3 to 100.0)                                              | 98.6 (97.2 to 99.9)                                                 |  |  |
| Week 24                           | 99.6 (98.9 to 100.0)                                              | 98.2 (96.7 to 99.7)                                                 |  |  |
| Week 28                           | 99.6 (98.9 to 100.0)                                              | 98.2 (96.7 to 99.7)                                                 |  |  |

|         |                      |                      |  |  |
|---------|----------------------|----------------------|--|--|
| Week 32 | 99.3 (98.3 to 100.0) | 98.2 (96.7 to 99.7)  |  |  |
| Week 36 | 99.6 (98.9 to 100.0) | 98.6 (97.2 to 100.0) |  |  |
| Week 40 | 98.9 (97.7 to 100.0) | 98.6 (97.2 to 100.0) |  |  |
| Week 44 | 99.3 (98.3 to 100.0) | 98.2 (96.7 to 99.8)  |  |  |
| Week 48 | 98.9 (97.7 to 100.0) | 98.2 (96.7 to 99.8)  |  |  |
| Week 52 | 98.6 (97.2 to 100.0) | 98.2 (96.7 to 99.8)  |  |  |
| Week 56 | 98.9 (97.7 to 100.0) | 97.9 (96.2 to 99.5)  |  |  |
| Week 60 | 98.9 (97.7 to 100.0) | 98.2 (96.7 to 99.8)  |  |  |
| Week 64 | 98.6 (97.2 to 99.9)  | 97.1 (95.2 to 99.1)  |  |  |
| Week 68 | 98.6 (97.2 to 100.0) | 97.9 (96.2 to 99.5)  |  |  |
| Week 72 | 98.2 (96.6 to 99.8)  | 97.9 (96.2 to 99.5)  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants Avoiding a Loss of $\geq 5$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Parts 1 and 2: Percentage of Participants Avoiding a Loss of $\geq 5$ Letters in BCVA from Baseline in the Study Eye at Specified Timepoints Through Week 72 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                              |
| Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$ and $\leq 54$ letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI. |                                                                                                                                                              |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Secondary                                                                                                                                                    |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                              |
| Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                              |

|                                   |                                                                   |                                                                     |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| <b>End point values</b>           | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |

| number (confidence interval 95%) |                      |                      |  |  |
|----------------------------------|----------------------|----------------------|--|--|
| Week 4                           | 97.1 (95.1 to 99.1)  | 98.6 (97.2 to 99.9)  |  |  |
| Week 8                           | 97.8 (96.1 to 99.5)  | 98.6 (97.2 to 99.9)  |  |  |
| Week 12                          | 97.8 (96.1 to 99.5)  | 98.9 (97.7 to 100.0) |  |  |
| Week 16                          | 97.8 (96.1 to 99.5)  | 98.2 (96.7 to 99.7)  |  |  |
| Week 20                          | 98.5 (97.1 to 99.9)  | 97.8 (96.2 to 99.5)  |  |  |
| Week 24                          | 98.6 (97.2 to 100.0) | 97.5 (95.7 to 99.3)  |  |  |
| Week 28                          | 98.2 (96.6 to 99.8)  | 97.5 (95.7 to 99.3)  |  |  |
| Week 32                          | 98.6 (97.2 to 99.9)  | 97.8 (96.2 to 99.5)  |  |  |
| Week 36                          | 98.2 (96.7 to 99.7)  | 97.5 (95.7 to 99.3)  |  |  |
| Week 40                          | 97.1 (95.2 to 99.0)  | 97.5 (95.6 to 99.3)  |  |  |
| Week 44                          | 98.6 (97.2 to 99.9)  | 97.8 (96.1 to 99.5)  |  |  |
| Week 48                          | 97.1 (95.2 to 99.0)  | 97.9 (96.2 to 99.5)  |  |  |
| Week 52                          | 97.1 (95.2 to 99.1)  | 97.5 (95.7 to 99.3)  |  |  |
| Week 56                          | 97.5 (95.6 to 99.3)  | 97.5 (95.7 to 99.3)  |  |  |
| Week 60                          | 97.8 (96.1 to 99.5)  | 96.8 (94.7 to 98.8)  |  |  |
| Week 64                          | 97.1 (95.1 to 99.1)  | 96.8 (94.7 to 98.8)  |  |  |
| Week 68                          | 97.1 (95.1 to 99.1)  | 97.1 (95.2 to 99.1)  |  |  |
| Week 72                          | 97.1 (95.1 to 99.1)  | 96.8 (94.7 to 98.8)  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                                             |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

### End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                                                                                          |           |
|------------------------------------------------------------------------------------------|-----------|
| End point type                                                                           | Secondary |
| End point timeframe:                                                                     |           |
| Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72 |           |

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 8.7 (5.5 to 11.9)                                                 | 8.6 (5.5 to 11.8)                                                   |  |  |
| Week 8                            | 14.1 (10.3 to 18.0)                                               | 15.5 (11.5 to 19.5)                                                 |  |  |
| Week 12                           | 15.6 (11.7 to 19.6)                                               | 20.2 (15.7 to 24.6)                                                 |  |  |
| Week 16                           | 17.4 (13.3 to 21.6)                                               | 22.0 (17.4 to 26.5)                                                 |  |  |
| Week 20                           | 20.7 (16.2 to 25.2)                                               | 23.8 (19.0 to 28.5)                                                 |  |  |
| Week 24                           | 22.9 (18.2 to 27.6)                                               | 23.8 (19.1 to 28.5)                                                 |  |  |
| Week 28                           | 24.0 (19.2 to 28.8)                                               | 25.6 (20.7 to 30.4)                                                 |  |  |
| Week 32                           | 25.1 (20.3 to 29.8)                                               | 23.4 (18.8 to 28.0)                                                 |  |  |
| Week 36                           | 25.1 (20.2 to 29.9)                                               | 25.2 (20.4 to 30.0)                                                 |  |  |
| Week 40                           | 26.9 (22.0 to 31.8)                                               | 22.0 (17.4 to 26.5)                                                 |  |  |
| Week 44                           | 26.8 (21.8 to 31.8)                                               | 24.8 (20.0 to 29.7)                                                 |  |  |
| Week 48                           | 29.0 (24.0 to 34.1)                                               | 25.2 (20.3 to 30.1)                                                 |  |  |
| Week 52                           | 26.8 (21.9 to 31.7)                                               | 25.6 (20.7 to 30.4)                                                 |  |  |
| Week 56                           | 26.1 (21.2 to 31.0)                                               | 22.0 (17.3 to 26.6)                                                 |  |  |
| Week 60                           | 27.6 (22.6 to 32.6)                                               | 25.6 (20.8 to 30.4)                                                 |  |  |
| Week 64                           | 30.1 (25.0 to 35.3)                                               | 24.5 (19.7 to 29.3)                                                 |  |  |
| Week 68                           | 29.4 (24.2 to 34.6)                                               | 25.9 (21.0 to 30.8)                                                 |  |  |
| Week 72                           | 29.4 (24.3 to 34.5)                                               | 24.8 (20.0 to 29.7)                                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                                                       |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 55.6 (50.6 to 60.5)                                               | 62.3 (57.3 to 67.3)                                                 |  |  |
| Week 8                            | 63.9 (59.3 to 68.6)                                               | 70.3 (65.7 to 74.9)                                                 |  |  |
| Week 12                           | 69.0 (64.4 to 73.6)                                               | 69.2 (64.4 to 74.0)                                                 |  |  |
| Week 16                           | 72.2 (67.7 to 76.8)                                               | 72.1 (67.5 to 76.8)                                                 |  |  |
| Week 20                           | 73.3 (69.1 to 77.6)                                               | 76.1 (71.7 to 80.5)                                                 |  |  |
| Week 24                           | 73.7 (69.3 to 78.1)                                               | 76.5 (71.9 to 81.0)                                                 |  |  |
| Week 28                           | 73.3 (68.7 to 77.9)                                               | 75.4 (70.7 to 80.0)                                                 |  |  |
| Week 32                           | 76.9 (72.6 to 81.2)                                               | 75.4 (70.7 to 80.1)                                                 |  |  |
| Week 36                           | 76.2 (71.8 to 80.6)                                               | 77.9 (73.3 to 82.5)                                                 |  |  |
| Week 40                           | 75.5 (71.0 to 79.9)                                               | 76.8 (72.3 to 81.3)                                                 |  |  |
| Week 44                           | 76.9 (72.4 to 81.4)                                               | 76.1 (71.4 to 80.7)                                                 |  |  |
| Week 48                           | 77.2 (72.7 to 81.8)                                               | 79.3 (75.0 to 83.7)                                                 |  |  |
| Week 52                           | 78.7 (74.3 to 83.1)                                               | 80.4 (76.1 to 84.7)                                                 |  |  |
| Week 56                           | 76.2 (71.5 to 80.9)                                               | 79.0 (74.5 to 83.5)                                                 |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 60 | 80.2 (75.8 to 84.5) | 79.0 (74.5 to 83.5) |  |  |
| Week 64 | 77.6 (73.0 to 82.2) | 81.1 (76.8 to 85.5) |  |  |
| Week 68 | 77.6 (73.0 to 82.2) | 80.4 (76.0 to 84.9) |  |  |
| Week 72 | 78.0 (73.5 to 82.4) | 79.0 (74.4 to 83.6) |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Parts 1 and 2: Percentage of Participants with $\leq 38$ Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                                                        |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants with $\leq 38$ Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA ( $>38$  and  $\leq 38$  letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 3.6 (2.0 to 5.3)                                                  | 1.5 (0.1 to 2.9)                                                    |  |  |
| Week 8                            | 3.2 (1.3 to 5.0)                                                  | 1.9 (0.5 to 3.3)                                                    |  |  |
| Week 12                           | 2.3 (0.8 to 3.8)                                                  | 1.5 (0.2 to 2.8)                                                    |  |  |
| Week 16                           | 2.3 (0.8 to 3.8)                                                  | 1.9 (0.4 to 3.3)                                                    |  |  |
| Week 20                           | 2.3 (0.8 to 3.8)                                                  | 1.9 (0.4 to 3.3)                                                    |  |  |
| Week 24                           | 2.3 (0.8 to 3.8)                                                  | 1.9 (0.4 to 3.3)                                                    |  |  |
| Week 28                           | 2.0 (0.6 to 3.5)                                                  | 1.9 (0.4 to 3.3)                                                    |  |  |
| Week 32                           | 2.4 (0.8 to 4.0)                                                  | 1.9 (0.4 to 3.3)                                                    |  |  |
| Week 36                           | 1.9 (0.5 to 3.4)                                                  | 1.5 (0.2 to 2.8)                                                    |  |  |
| Week 40                           | 2.3 (0.8 to 3.7)                                                  | 1.5 (0.2 to 2.8)                                                    |  |  |
| Week 44                           | 2.7 (1.0 to 4.4)                                                  | 1.5 (0.2 to 2.8)                                                    |  |  |

|         |                  |                  |  |  |
|---------|------------------|------------------|--|--|
| Week 48 | 2.4 (0.8 to 4.0) | 2.2 (0.6 to 3.9) |  |  |
| Week 52 | 3.1 (1.3 to 4.9) | 2.6 (0.9 to 4.3) |  |  |
| Week 56 | 2.7 (1.0 to 4.4) | 2.6 (0.9 to 4.3) |  |  |
| Week 60 | 2.1 (0.6 to 3.6) | 2.6 (0.9 to 4.3) |  |  |
| Week 64 | 3.1 (1.3 to 4.9) | 2.2 (0.6 to 3.9) |  |  |
| Week 68 | 2.1 (0.6 to 3.6) | 1.8 (0.3 to 3.3) |  |  |
| Week 72 | 2.1 (0.6 to 3.6) | 2.2 (0.5 to 3.9) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Change from Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72

|                 |                                                                                                                         |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Change from Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|

End point description:

The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the MMRM analysis, the model adjusted for the treatment group, visit, visit-by-treatment group interaction, baseline NEI VFQ-25 Composite Score continuous), baseline BCVA score ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were implicitly imputed. Invalid BCVA values were excluded. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 24, 48, and 72

| End point values                          | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                        | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed               | 276                                                               | 277                                                                 |  |  |
| Units: score on a scale                   |                                                                   |                                                                     |  |  |
| arithmetic mean (confidence interval 95%) |                                                                   |                                                                     |  |  |
| Week 24                                   | 5.6 (4.5 to 6.6)                                                  | 5.9 (4.9 to 7.0)                                                    |  |  |
| Week 48                                   | 6.4 (5.3 to 7.5)                                                  | 6.3 (5.2 to 7.4)                                                    |  |  |
| Week 72                                   | 6.0 (4.8 to 7.3)                                                  | 7.8 (6.6 to 9.0)                                                    |  |  |

## Statistical analyses

No statistical analyses for this end point



## Secondary: Parts 1 and 2: Change from Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Parts 1 and 2: Change from Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                            |
| Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors [baseline BCVA ( $\geq 55$ and $\leq 54$ letters), and region (U.S. and Canada, Asia, and rest of the world)] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI. |                                                                                                                            |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary                                                                                                                  |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                            |
| Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                            |

| End point values                          | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                        | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed               | 276                                                               | 277                                                                 |  |  |
| Units: microns                            |                                                                   |                                                                     |  |  |
| arithmetic mean (confidence interval 95%) |                                                                   |                                                                     |  |  |
| Week 4                                    | -287.3 (-293.5 to -281.1)                                         | -284.3 (-290.4 to -278.2)                                           |  |  |
| Week 8                                    | -302.9 (-308.7 to -297.2)                                         | -300.2 (-306.0 to -294.5)                                           |  |  |
| Week 12                                   | -307.8 (-313.1 to -302.6)                                         | -301.9 (-307.1 to -296.7)                                           |  |  |
| Week 16                                   | -309.3 (-314.6 to -304.0)                                         | -304.5 (-309.8 to -299.3)                                           |  |  |
| Week 20                                   | -310.6 (-315.5 to -305.6)                                         | -304.2 (-309.1 to -299.3)                                           |  |  |
| Week 24                                   | -314.5 (-319.5 to -309.6)                                         | -307.6 (-312.5 to -302.7)                                           |  |  |
| Week 28                                   | -294.0 (-302.2 to -285.8)                                         | -285.1 (-293.3 to -276.9)                                           |  |  |
| Week 32                                   | -308.3 (-314.6 to -302.0)                                         | -303.2 (-309.4 to -297.0)                                           |  |  |
| Week 36                                   | -304.1 (-310.6 to -297.6)                                         | -298.8 (-305.2 to -292.4)                                           |  |  |
| Week 40                                   | -296.7 (-304.4 to -288.9)                                         | -285.8 (-293.7 to -278.0)                                           |  |  |
| Week 44                                   | -309.2 (-315.9 to -302.5)                                         | -301.6 (-308.3 to -294.9)                                           |  |  |
| Week 48                                   | -309.4 (-315.3 to -303.5)                                         | -302.8 (-308.7 to -296.9)                                           |  |  |
| Week 52                                   | -302.2 (-308.6 to -295.7)                                         | -302.4 (-308.8 to -296.0)                                           |  |  |
| Week 56                                   | -294.0 (-302.6 to -285.5)                                         | -288.0 (-296.6 to -279.4)                                           |  |  |

|         |                           |                           |  |  |
|---------|---------------------------|---------------------------|--|--|
| Week 60 | -309.5 (-315.1 to -303.9) | -306.2 (-311.9 to -300.6) |  |  |
| Week 64 | -311.1 (-316.3 to -305.9) | -305.9 (-311.1 to -300.7) |  |  |
| Week 68 | -311.2 (-316.3 to -306.1) | -307.9 (-313.0 to -302.8) |  |  |
| Week 72 | -310.5 (-315.7 to -305.4) | -307.2 (-312.3 to -302.0) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants with Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                  |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants with Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|

End point description:

Absence of diabetic macular edema was defined as achieving a central subfield thickness of <325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 88.8 (85.1 to 92.5)                                               | 88.1 (84.4 to 91.9)                                                 |  |  |
| Week 8                            | 94.5 (91.9 to 97.2)                                               | 93.2 (90.3 to 96.1)                                                 |  |  |
| Week 12                           | 96.4 (94.2 to 98.5)                                               | 92.1 (89.0 to 95.2)                                                 |  |  |
| Week 16                           | 95.3 (92.8 to 97.7)                                               | 93.6 (90.7 to 96.4)                                                 |  |  |
| Week 20                           | 96.0 (93.7 to 98.3)                                               | 94.6 (92.1 to 97.2)                                                 |  |  |
| Week 24                           | 95.6 (93.3 to 98.0)                                               | 94.3 (91.6 to 96.9)                                                 |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 28 | 89.1 (85.5 to 92.8) | 86.0 (82.0 to 90.0) |  |  |
| Week 32 | 94.6 (91.9 to 97.2) | 92.5 (89.4 to 95.5) |  |  |
| Week 36 | 93.8 (91.1 to 96.5) | 90.7 (87.3 to 94.0) |  |  |
| Week 40 | 89.5 (85.9 to 93.0) | 84.2 (79.9 to 88.4) |  |  |
| Week 44 | 96.0 (93.7 to 98.3) | 92.1 (88.9 to 95.2) |  |  |
| Week 48 | 94.9 (92.4 to 97.5) | 91.4 (88.1 to 94.6) |  |  |
| Week 52 | 92.4 (89.3 to 95.5) | 91.4 (88.2 to 94.6) |  |  |
| Week 56 | 89.5 (85.9 to 93.1) | 86.3 (82.3 to 90.3) |  |  |
| Week 60 | 94.2 (91.5 to 96.9) | 93.9 (91.1 to 96.7) |  |  |
| Week 64 | 95.3 (92.8 to 97.8) | 93.9 (91.1 to 96.7) |  |  |
| Week 68 | 94.9 (92.4 to 97.5) | 92.4 (89.4 to 95.5) |  |  |
| Week 72 | 94.2 (91.5 to 96.9) | 94.2 (91.5 to 97.0) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants with Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                       |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants with Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |

| number (confidence interval 95%) |                     |                     |  |  |
|----------------------------------|---------------------|---------------------|--|--|
| Week 4                           | 46.1 (40.2 to 51.9) | 54.8 (49.0 to 60.6) |  |  |
| Week 8                           | 53.8 (48.2 to 59.4) | 57.4 (51.6 to 63.1) |  |  |
| Week 12                          | 65.3 (59.7 to 70.8) | 56.6 (50.8 to 62.4) |  |  |
| Week 16                          | 69.9 (64.6 to 75.3) | 72.9 (67.8 to 78.1) |  |  |
| Week 20                          | 67.1 (61.6 to 72.6) | 66.4 (60.9 to 71.9) |  |  |
| Week 24                          | 73.9 (68.9 to 79.0) | 69.3 (63.9 to 74.7) |  |  |
| Week 28                          | 54.4 (48.7 to 60.2) | 47.6 (41.8 to 53.5) |  |  |
| Week 32                          | 68.1 (62.6 to 73.6) | 65.0 (59.4 to 70.6) |  |  |
| Week 36                          | 60.9 (55.1 to 66.6) | 56.0 (50.2 to 61.7) |  |  |
| Week 40                          | 50.8 (45.0 to 56.6) | 48.1 (42.3 to 53.9) |  |  |
| Week 44                          | 70.3 (64.9 to 75.6) | 63.9 (58.3 to 69.6) |  |  |
| Week 48                          | 76.1 (71.1 to 81.1) | 67.9 (62.5 to 73.3) |  |  |
| Week 52                          | 55.8 (50.0 to 61.7) | 56.7 (50.9 to 62.5) |  |  |
| Week 56                          | 58.4 (52.6 to 64.1) | 58.9 (53.2 to 64.6) |  |  |
| Week 60                          | 75.0 (69.9 to 80.1) | 72.6 (67.4 to 77.7) |  |  |
| Week 64                          | 75.8 (70.9 to 80.7) | 69.7 (64.3 to 75.1) |  |  |
| Week 68                          | 69.9 (64.5 to 75.3) | 68.6 (63.2 to 74.1) |  |  |
| Week 72                          | 72.8 (67.6 to 78.0) | 72.9 (67.7 to 78.1) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants with Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                     |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants with Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| <b>End point values</b>           | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 76.1 (71.1 to 81.1)                                               | 72.9 (67.8 to 78.1)                                                 |  |  |
| Week 8                            | 93.1 (90.2 to 96.1)                                               | 91.4 (88.1 to 94.6)                                                 |  |  |
| Week 12                           | 96.4 (94.2 to 98.6)                                               | 97.1 (95.2 to 99.1)                                                 |  |  |
| Week 16                           | 95.3 (92.8 to 97.8)                                               | 96.4 (94.2 to 98.6)                                                 |  |  |
| Week 20                           | 98.2 (96.6 to 99.8)                                               | 97.8 (96.1 to 99.5)                                                 |  |  |
| Week 24                           | 91.3 (88.0 to 94.6)                                               | 90.3 (86.9 to 93.7)                                                 |  |  |
| Week 28                           | 93.5 (90.7 to 96.4)                                               | 91.0 (87.6 to 94.3)                                                 |  |  |
| Week 32                           | 96.4 (94.2 to 98.6)                                               | 97.1 (95.2 to 99.1)                                                 |  |  |
| Week 36                           | 97.1 (95.1 to 99.1)                                               | 96.0 (93.7 to 98.3)                                                 |  |  |
| Week 40                           | 96.8 (94.7 to 98.8)                                               | 95.7 (93.3 to 98.1)                                                 |  |  |
| Week 44                           | 97.5 (95.7 to 99.3)                                               | 95.7 (93.3 to 98.0)                                                 |  |  |
| Week 48                           | 97.1 (95.1 to 99.1)                                               | 94.6 (91.9 to 97.2)                                                 |  |  |
| Week 52                           | 98.2 (96.6 to 99.8)                                               | 97.1 (95.2 to 99.1)                                                 |  |  |
| Week 56                           | 95.3 (92.8 to 97.8)                                               | 95.0 (92.4 to 97.5)                                                 |  |  |
| Week 60                           | 95.7 (93.3 to 98.1)                                               | 96.0 (93.8 to 98.3)                                                 |  |  |
| Week 64                           | 98.2 (96.7 to 99.7)                                               | 96.8 (94.7 to 98.8)                                                 |  |  |
| Week 68                           | 97.5 (95.6 to 99.3)                                               | 97.5 (95.7 to 99.3)                                                 |  |  |
| Week 72                           | 96.4 (94.2 to 98.6)                                               | 94.9 (92.4 to 97.5)                                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 2: Percentage of Participants with Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                           |
|-----------------|-----------------------------------------------------------|
| End point title | Parts 1 and 2: Percentage of Participants with Absence of |
|-----------------|-----------------------------------------------------------|

End point description:

Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed       | 276                                                               | 277                                                                 |  |  |
| Units: Percentage of participants |                                                                   |                                                                     |  |  |
| number (confidence interval 95%)  |                                                                   |                                                                     |  |  |
| Week 4                            | 37.8 (32.1 to 43.4)                                               | 40.8 (35.2 to 46.4)                                                 |  |  |
| Week 8                            | 50.9 (45.3 to 56.5)                                               | 54.1 (48.4 to 59.9)                                                 |  |  |
| Week 12                           | 63.8 (58.2 to 69.4)                                               | 56.3 (50.5 to 62.1)                                                 |  |  |
| Week 16                           | 67.1 (61.6 to 72.6)                                               | 72.6 (67.4 to 77.8)                                                 |  |  |
| Week 20                           | 66.0 (60.5 to 71.5)                                               | 66.0 (60.5 to 71.6)                                                 |  |  |
| Week 24                           | 67.4 (61.9 to 72.9)                                               | 64.3 (58.6 to 69.9)                                                 |  |  |
| Week 28                           | 53.0 (47.2 to 58.7)                                               | 46.9 (41.1 to 52.8)                                                 |  |  |
| Week 32                           | 67.4 (61.9 to 72.9)                                               | 64.6 (59.0 to 70.2)                                                 |  |  |
| Week 36                           | 60.5 (54.8 to 66.3)                                               | 54.2 (48.4 to 59.9)                                                 |  |  |
| Week 40                           | 50.4 (44.6 to 56.2)                                               | 47.3 (41.5 to 53.2)                                                 |  |  |
| Week 44                           | 69.6 (64.2 to 74.9)                                               | 63.6 (57.9 to 69.2)                                                 |  |  |
| Week 48                           | 74.7 (69.6 to 79.8)                                               | 65.4 (59.8 to 70.9)                                                 |  |  |
| Week 52                           | 55.5 (49.6 to 61.3)                                               | 55.6 (49.8 to 61.4)                                                 |  |  |
| Week 56                           | 58.0 (52.2 to 63.8)                                               | 57.8 (52.0 to 63.6)                                                 |  |  |
| Week 60                           | 73.9 (68.8 to 79.1)                                               | 70.4 (65.1 to 75.7)                                                 |  |  |
| Week 64                           | 75.4 (70.5 to 80.4)                                               | 69.3 (64.0 to 74.7)                                                 |  |  |
| Week 68                           | 68.9 (63.4 to 74.3)                                               | 68.3 (62.8 to 73.7)                                                 |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 72 | 70.7 (65.3 to 76.0) | 71.1 (65.8 to 76.4) |  |  |
|---------|---------------------|---------------------|--|--|

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 2: Change from Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Part 2: Change from Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                              |
| Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors [baseline BCVA ( $\geq 55$ and $\leq 54$ letters), and region (U.S. and Canada, Asia, and rest of the world)] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI. |                                                                                              |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Secondary                                                                                    |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                              |
| Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                              |

| End point values                          | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |  |  |
|-------------------------------------------|---------------------------------------------------------|--------------------------------------------------------------|--|--|
| Subject group type                        | Subject analysis set                                    | Subject analysis set                                         |  |  |
| Number of subjects analysed               | 276                                                     | 277                                                          |  |  |
| Units: ETDRS Letters                      |                                                         |                                                              |  |  |
| arithmetic mean (confidence interval 95%) |                                                         |                                                              |  |  |
| Week 28                                   | -0.3 (-0.8 to 0.3)                                      | -0.1 (-0.6 to 0.5)                                           |  |  |
| Week 32                                   | 0.5 (-0.1 to 1.0)                                       | 0.0 (-0.6 to 0.5)                                            |  |  |
| Week 36                                   | 0.5 (-0.2 to 1.2)                                       | 0.6 (-0.1 to 1.2)                                            |  |  |
| Week 40                                   | 0.3 (-0.4 to 1.1)                                       | 0.4 (-0.3 to 1.2)                                            |  |  |
| Week 44                                   | 1.1 (0.3 to 1.9)                                        | 0.3 (-0.5 to 1.1)                                            |  |  |
| Week 48                                   | 1.1 (0.3 to 2.0)                                        | 0.7 (-0.1 to 1.6)                                            |  |  |
| Week 52                                   | 1.1 (0.2 to 2.0)                                        | 0.9 (0.0 to 1.8)                                             |  |  |
| Week 56                                   | 0.4 (-0.5 to 1.4)                                       | 0.6 (-0.3 to 1.6)                                            |  |  |
| Week 60                                   | 1.0 (0.1 to 2.0)                                        | 1.1 (0.1 to 2.0)                                             |  |  |

|         |                  |                  |  |  |
|---------|------------------|------------------|--|--|
| Week 64 | 0.9 (0.0 to 1.9) | 1.2 (0.2 to 2.2) |  |  |
| Week 68 | 1.2 (0.2 to 2.1) | 1.3 (0.4 to 2.2) |  |  |
| Week 72 | 1.5 (0.5 to 2.5) | 1.3 (0.3 to 2.3) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 2: Percentage of Participants Avoiding a Loss of $\geq 15$ Letters in BCVA from Week 24 in the Study Eye at Specified Timepoints Through Week 72

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Part 2: Percentage of Participants Avoiding a Loss of $\geq 15$ Letters in BCVA from Week 24 in the Study Eye at Specified Timepoints Through Week 72 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                       |
| Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$ and $\leq 54$ letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI. |                                                                                                                                                       |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Secondary                                                                                                                                             |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                       |
| Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                       |

| End point values                  | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|---------------------------------------------------------|--------------------------------------------------------------|--|--|
| Subject group type                | Subject analysis set                                    | Subject analysis set                                         |  |  |
| Number of subjects analysed       | 276                                                     | 277                                                          |  |  |
| Units: Percentage of participants |                                                         |                                                              |  |  |
| number (confidence interval 95%)  |                                                         |                                                              |  |  |
| Week 28                           | 85.5 (81.4 to 89.6)                                     | 84.1 (79.8 to 88.3)                                          |  |  |
| Week 32                           | 89.1 (85.5 to 92.7)                                     | 87.7 (83.9 to 91.5)                                          |  |  |
| Week 36                           | 89.5 (85.9 to 93.1)                                     | 88.4 (84.7 to 92.2)                                          |  |  |
| Week 40                           | 89.5 (85.9 to 93.0)                                     | 88.0 (84.2 to 91.8)                                          |  |  |
| Week 44                           | 89.9 (86.3 to 93.4)                                     | 86.3 (82.2 to 90.3)                                          |  |  |
| Week 48                           | 89.5 (85.9 to 93.1)                                     | 86.6 (82.6 to 90.6)                                          |  |  |
| Week 52                           | 89.9 (86.3 to 93.4)                                     | 87.7 (83.9 to 91.6)                                          |  |  |
| Week 56                           | 88.0 (84.3 to 91.8)                                     | 86.6 (82.6 to 90.6)                                          |  |  |



|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 60 | 88.8 (85.1 to 92.5) | 87.0 (83.0 to 90.9) |  |  |
| Week 64 | 89.5 (85.9 to 93.1) | 86.6 (82.6 to 90.6) |  |  |
| Week 68 | 88.4 (84.7 to 92.1) | 87.0 (83.0 to 90.9) |  |  |
| Week 72 | 88.4 (84.7 to 92.1) | 87.0 (83.0 to 90.9) |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 2: Percentage of Participants Avoiding a Loss of $\geq 10$ Letters in BCVA from Week 24 in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 2: Percentage of Participants Avoiding a Loss of $\geq 10$ Letters in BCVA from Week 24 in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|---------------------------------------------------------|--------------------------------------------------------------|--|--|
| Subject group type                | Subject analysis set                                    | Subject analysis set                                         |  |  |
| Number of subjects analysed       | 276                                                     | 277                                                          |  |  |
| Units: Percentage of participants |                                                         |                                                              |  |  |
| number (confidence interval 95%)  |                                                         |                                                              |  |  |
| Week 28                           | 84.8 (80.6 to 89.0)                                     | 82.3 (77.8 to 86.7)                                          |  |  |
| Week 32                           | 88.8 (85.1 to 92.5)                                     | 85.9 (81.8 to 89.9)                                          |  |  |
| Week 36                           | 87.3 (83.4 to 91.2)                                     | 87.0 (83.0 to 90.9)                                          |  |  |
| Week 40                           | 87.7 (83.8 to 91.5)                                     | 86.3 (82.2 to 90.3)                                          |  |  |
| Week 44                           | 88.8 (85.1 to 92.5)                                     | 85.5 (81.4 to 89.7)                                          |  |  |
| Week 48                           | 88.4 (84.7 to 92.2)                                     | 85.2 (81.0 to 89.3)                                          |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 52 | 88.4 (84.7 to 92.2) | 85.2 (81.0 to 89.3) |  |  |
| Week 56 | 86.2 (82.2 to 90.2) | 83.4 (79.0 to 87.7) |  |  |
| Week 60 | 86.9 (83.0 to 90.9) | 83.4 (79.0 to 87.7) |  |  |
| Week 64 | 86.9 (83.0 to 90.9) | 85.2 (81.0 to 89.4) |  |  |
| Week 68 | 86.6 (82.6 to 90.6) | 85.5 (81.4 to 89.7) |  |  |
| Week 72 | 86.6 (82.6 to 90.6) | 85.5 (81.4 to 89.7) |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 2: Percentage of Participants Avoiding a Loss of $\geq 5$ Letters in BCVA from Week 24 in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                                      |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 2: Percentage of Participants Avoiding a Loss of $\geq 5$ Letters in BCVA from Week 24 in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|---------------------------------------------------------|--------------------------------------------------------------|--|--|
| Subject group type                | Subject analysis set                                    | Subject analysis set                                         |  |  |
| Number of subjects analysed       | 276                                                     | 277                                                          |  |  |
| Units: Percentage of participants |                                                         |                                                              |  |  |
| number (confidence interval 95%)  |                                                         |                                                              |  |  |
| Week 28                           | 74.6 (69.5 to 79.7)                                     | 73.6 (68.5 to 78.8)                                          |  |  |
| Week 32                           | 80.0 (75.4 to 84.7)                                     | 77.2 (72.3 to 82.1)                                          |  |  |
| Week 36                           | 79.7 (75.0 to 84.4)                                     | 79.0 (74.2 to 83.8)                                          |  |  |
| Week 40                           | 78.6 (73.8 to 83.4)                                     | 78.3 (73.5 to 83.1)                                          |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 44 | 83.3 (79.0 to 87.7) | 76.9 (71.9 to 81.9) |  |  |
| Week 48 | 82.6 (78.2 to 87.0) | 79.4 (74.6 to 84.1) |  |  |
| Week 52 | 81.5 (77.0 to 86.0) | 79.4 (74.6 to 84.1) |  |  |
| Week 56 | 76.4 (71.5 to 81.3) | 78.3 (73.5 to 83.1) |  |  |
| Week 60 | 79.0 (74.2 to 83.7) | 77.2 (72.3 to 82.1) |  |  |
| Week 64 | 77.9 (73.0 to 82.8) | 76.1 (71.1 to 81.1) |  |  |
| Week 68 | 78.2 (73.4 to 83.1) | 76.5 (71.6 to 81.5) |  |  |
| Week 72 | 77.5 (72.7 to 82.4) | 77.6 (72.7 to 82.5) |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA from Week 24 in the Study Eye at Specified Timepoints Through Week 72

|                 |                                                                                                                                                |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Part 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA from Week 24 in the Study Eye at Specified Timepoints Through Week 72 |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors [baseline BCVA ( $\geq 55$  and  $\leq 54$  letters), and region (U.S. and Canada, Asia, and rest of the world)]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------|---------------------------------------------------------|--------------------------------------------------------------|--|--|
| Subject group type                | Subject analysis set                                    | Subject analysis set                                         |  |  |
| Number of subjects analysed       | 276                                                     | 277                                                          |  |  |
| Units: Percentage of participants |                                                         |                                                              |  |  |
| number (confidence interval 95%)  |                                                         |                                                              |  |  |
| Week 28                           | 46.4 (40.6 to 52.3)                                     | 51.3 (45.4 to 57.1)                                          |  |  |
| Week 32                           | 55.4 (49.6 to 61.2)                                     | 54.2 (48.3 to 60.0)                                          |  |  |

|         |                     |                     |  |  |
|---------|---------------------|---------------------|--|--|
| Week 36 | 55.1 (49.2 to 60.9) | 52.7 (46.9 to 58.6) |  |  |
| Week 40 | 56.2 (50.4 to 62.0) | 55.2 (49.4 to 61.1) |  |  |
| Week 44 | 62.4 (56.7 to 68.0) | 56.0 (50.1 to 61.8) |  |  |
| Week 48 | 63.8 (58.2 to 69.4) | 56.6 (50.9 to 62.4) |  |  |
| Week 52 | 59.8 (54.1 to 65.5) | 58.5 (52.7 to 64.3) |  |  |
| Week 56 | 57.2 (51.5 to 63.0) | 57.4 (51.5 to 63.2) |  |  |
| Week 60 | 58.0 (52.1 to 63.8) | 60.3 (54.5 to 66.0) |  |  |
| Week 64 | 62.0 (56.3 to 67.7) | 56.6 (50.8 to 62.5) |  |  |
| Week 68 | 60.9 (55.1 to 66.6) | 58.8 (53.1 to 64.6) |  |  |
| Week 72 | 63.0 (57.4 to 68.7) | 58.1 (52.3 to 63.9) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 2: Percentage of Participants on Different Treatment Intervals at Week 68

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Part 2: Percentage of Participants on Different Treatment Intervals at Week 68 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                |
| In Part 2 of the study, participants in both the faricimab Q4W and aflibercept Q4W arms in Part 1 received 6 mg faricimab intravitreal injections administered according to a personalized treatment interval (PTI) dosing regimen in intervals between Q4W and Q16W. At faricimab dosing visits, treatment intervals were maintained or adjusted (i.e., increased by 4 weeks or decreased by 4, 8, or 12 weeks), based on central subfield thickness (CST) and BCVA values. |                                                                                |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Secondary                                                                      |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                |
| Week 68                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                |

| End point values                  | Arm A:<br>Faricimab Q4W to Faricimab PTI (Part 2) | Arm B:<br>Aflibercept Q4W to Faricimab PTI (Part 2) |  |  |
|-----------------------------------|---------------------------------------------------|-----------------------------------------------------|--|--|
| Subject group type                | Subject analysis set                              | Subject analysis set                                |  |  |
| Number of subjects analysed       | 248                                               | 244                                                 |  |  |
| Units: Percentage of participants |                                                   |                                                     |  |  |
| number (confidence interval 95%)  |                                                   |                                                     |  |  |
| Once Every 4 Weeks (Q4W)          | 22.6 (17.4 to 27.8)                               | 25.0 (19.6 to 30.4)                                 |  |  |
| Once Every 8 Weeks (Q8W)          | 13.3 (9.1 to 17.5)                                | 18.0 (13.2 to 22.9)                                 |  |  |

|                            |                     |                     |  |  |
|----------------------------|---------------------|---------------------|--|--|
| Once Every 12 Weeks (Q12W) | 11.7 (7.7 to 15.7)  | 9.4 (5.8 to 13.1)   |  |  |
| Once Every 16 Weeks (Q16W) | 52.4 (46.2 to 58.6) | 47.5 (41.3 to 53.8) |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Incidence and Severity of Ocular Adverse Events in the Study Eye, with Severity Determined According to Adverse Event Severity Grading Scale

|                 |                                                                                                                                              |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Incidence and Severity of Ocular Adverse Events in the Study Eye, with Severity Determined According to Adverse Event Severity Grading Scale |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

This analysis of adverse events (AEs) only includes ocular AEs that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score  $\geq 30$  letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

| End point values                              | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |
|-----------------------------------------------|-------------------------------------|---------------------------------------|---------------------------------------------------------|--------------------------------------------------------------|
| Subject group type                            | Subject analysis set                | Subject analysis set                  | Subject analysis set                                    | Subject analysis set                                         |
| Number of subjects analysed                   | 276                                 | 274                                   | 270                                                     | 267                                                          |
| Units: Participants                           |                                     |                                       |                                                         |                                                              |
| Adverse Event (AE)                            | 45                                  | 56                                    | 76                                                      | 81                                                           |
| AE by Severity: Mild                          | 40                                  | 47                                    | 50                                                      | 64                                                           |
| AE by Severity: Moderate                      | 4                                   | 8                                     | 25                                                      | 16                                                           |
| AE by Severity: Severe                        | 0                                   | 1                                     | 1                                                       | 1                                                            |
| AE by Severity: Missing                       | 1                                   | 0                                     | 0                                                       | 0                                                            |
| Serious Adverse Event (SAE)                   | 3                                   | 2                                     | 4                                                       | 3                                                            |
| AE Leading to Withdrawal from Study Treatment | 0                                   | 0                                     | 0                                                       | 1                                                            |
| Treatment Related AEs                         | 1                                   | 3                                     | 7                                                       | 8                                                            |
| Treatment Related SAEs                        | 0                                   | 0                                     | 0                                                       | 0                                                            |
| Any AE of Special Interest (AESI)             | 1                                   | 2                                     | 1                                                       | 1                                                            |
| AESI: Drop in Visual Acuity Score $\geq 30$   | 1                                   | 2                                     | 1                                                       | 1                                                            |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 2: Number of Study Drug Injections Received in the Study Eye from Week 24 Through Week 72

|                 |                                                                                                |
|-----------------|------------------------------------------------------------------------------------------------|
| End point title | Part 2: Number of Study Drug Injections Received in the Study Eye from Week 24 Through Week 72 |
|-----------------|------------------------------------------------------------------------------------------------|

End point description:

Safety-Evaluable Population: All participants randomized in the study who received at least one injection of active study drug in the study eye. For Part 2, the safety analysis included: in Arm A, all participants with Week 24 treatment or dose hold, or if none, follow-up beyond Day 168; in Arm B, all participants who received at least one faricimab dose.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Week 24 to Week 72

| End point values              | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |  |  |
|-------------------------------|---------------------------------------------------------|--------------------------------------------------------------|--|--|
| Subject group type            | Subject analysis set                                    | Subject analysis set                                         |  |  |
| Number of subjects analysed   | 270                                                     | 267                                                          |  |  |
| Units: Injections             |                                                         |                                                              |  |  |
| median (full range (min-max)) | 4.0 (1 to 12)                                           | 4.0 (1 to 12)                                                |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Incidence of Non-Ocular Adverse Events

|                 |                                        |
|-----------------|----------------------------------------|
| End point title | Incidence of Non-Ocular Adverse Events |
|-----------------|----------------------------------------|

End point description:

This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

| End point values                                 | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |
|--------------------------------------------------|-------------------------------------|---------------------------------------|---------------------------------------------------------|--------------------------------------------------------------|
| Subject group type                               | Subject analysis set                | Subject analysis set                  | Subject analysis set                                    | Subject analysis set                                         |
| Number of subjects analysed                      | 276                                 | 274                                   | 270                                                     | 267                                                          |
| Units: Participants                              |                                     |                                       |                                                         |                                                              |
| Adverse Event (AE)                               | 94                                  | 99                                    | 136                                                     | 126                                                          |
| Serious Adverse Event (SAE)                      | 9                                   | 16                                    | 25                                                      | 23                                                           |
| AE Leading to Withdrawal from Study<br>Treatment | 1                                   | 0                                     | 0                                                       | 3                                                            |
| Any AE of Special Interest (AESI)                | 0                                   | 0                                     | 0                                                       | 0                                                            |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Incidence of Ocular Adverse Events in the Fellow Eye

|                 |                                                      |
|-----------------|------------------------------------------------------|
| End point title | Incidence of Ocular Adverse Events in the Fellow Eye |
|-----------------|------------------------------------------------------|

End point description:

This analysis of adverse events (AEs) only includes ocular AEs that occurred in the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score  $\geq 30$  letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

| End point values                  | Arm A:<br>Faricimab Q4W<br>(Part 1) | Arm B:<br>Aflibercept<br>Q4W (Part 1) | Arm A:<br>Faricimab Q4W<br>to Faricimab<br>PTI (Part 2) | Arm B:<br>Aflibercept<br>Q4W to<br>Faricimab PTI<br>(Part 2) |
|-----------------------------------|-------------------------------------|---------------------------------------|---------------------------------------------------------|--------------------------------------------------------------|
| Subject group type                | Subject analysis set                | Subject analysis set                  | Subject analysis set                                    | Subject analysis set                                         |
| Number of subjects analysed       | 276                                 | 274                                   | 270                                                     | 267                                                          |
| Units: Participants               |                                     |                                       |                                                         |                                                              |
| Adverse Event (AE)                | 25                                  | 21                                    | 37                                                      | 30                                                           |
| Serious Adverse Event (SAE)       | 0                                   | 0                                     | 0                                                       | 0                                                            |
| Any AE of Special Interest (AESI) | 0                                   | 0                                     | 0                                                       | 0                                                            |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Plasma Concentration of Faricimab Over Time

|                 |                                             |
|-----------------|---------------------------------------------|
| End point title | Plasma Concentration of Faricimab Over Time |
|-----------------|---------------------------------------------|

End point description:

Pharmacokinetic-Evaluable Population: All safety- evaluable participants randomized to faricimab arm or who received faricimab with at least one plasma sample, provided sufficient dosing information (dose and dosing time) is available. The number analyzed indicates all participants who provided a PK sample at a given timepoint. The values '999999' indicate that 0 participants provided samples at that timepoint, and therefore, there were no results to report.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72

| End point values                        | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) |  |  |
|-----------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type                      | Reporting group                                                   | Reporting group                                                     |  |  |
| Number of subjects analysed             | 276                                                               | 268                                                                 |  |  |
| Units: microgram per millilitre (µg/mL) |                                                                   |                                                                     |  |  |
| arithmetic mean (standard deviation)    |                                                                   |                                                                     |  |  |
| Baseline (n = 273, 0)                   | 0.0000 (±<br>0.0000)                                              | 999999 (±<br>999999)                                                |  |  |
| Week 4 (n = 264, 0)                     | 0.0215 (±<br>0.0160)                                              | 999999 (±<br>999999)                                                |  |  |
| Week 24 (n = 247, 241)                  | 0.0220 (±<br>0.0181)                                              | 0.0005 (±<br>0.0006)                                                |  |  |
| Week 28 (n = 238, 242)                  | 0.0040 (±<br>0.0072)                                              | 0.0025 (±<br>0.077)                                                 |  |  |
| Week 52 (n = 231, 224)                  | 0.0061 (±<br>0.0110)                                              | 0.0097 (±<br>0.0156)                                                |  |  |
| Week 72 (n = 231, 229)                  | 0.0076 (±<br>0.0109)                                              | 0.0087 (±<br>0.0146)                                                |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study

|                 |                                                                                                                     |
|-----------------|---------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study |
|-----------------|---------------------------------------------------------------------------------------------------------------------|

End point description:

Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The number of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period. Treatment-unaffected ADA-positive is a post-baseline sample with a titer that is lower than 4-fold the ADA-positive baseline titer (faricimab arm) or the ADA-positive titer prior to first faricimab injection (aflibercept arm).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|



---

End point timeframe:

Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72

---

| <b>End point values</b>                    | Arm A:<br>Faricimab Q4W<br>(Part 1),<br>Faricimab PTI<br>(Part 2) | Arm B:<br>Aflibercept<br>Q4W (Part 1),<br>Faricimab PTI<br>(Part 2) | All Faricimab<br>Participants |  |
|--------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------|--|
| Subject group type                         | Reporting group                                                   | Reporting group                                                     | Subject analysis set          |  |
| Number of subjects analysed                | 274                                                               | 266                                                                 | 540                           |  |
| Units: Participants                        |                                                                   |                                                                     |                               |  |
| Baseline (BL): Total ADA-Positive          | 3                                                                 | 4                                                                   | 7                             |  |
| Post-BL: Total ADA-Positive                | 33                                                                | 23                                                                  | 56                            |  |
| Post-BL: Treatment-Emergent ADA-Positive   | 32                                                                | 21                                                                  | 53                            |  |
| Post-BL: Treatment-Unaffected ADA-Positive | 1                                                                 | 2                                                                   | 3                             |  |

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

Adverse event reporting additional description:

Safety analysis population: all subjects who received  $\geq 1$  study drug injection (faricimab or aflibercept). For Part 2, this included: in Arm A, those with Week 24 treatment or dose hold, or if none, follow-up beyond Day 168; in Arm B, those who received  $\geq 1$  faricimab dose. The eye type (study/fellow) in which an ocular AE had occurred is specified.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 26.0 |
|--------------------|------|

### Reporting groups

|                       |                               |
|-----------------------|-------------------------------|
| Reporting group title | Arm A: Faricimab Q4W (Part 1) |
|-----------------------|-------------------------------|

Reporting group description:

In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A were to receive faricimab 6 milligrams (mg) administered by intravitreal (IVT) injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).

|                       |                                 |
|-----------------------|---------------------------------|
| Reporting group title | Arm B: Aflibercept Q4W (Part 1) |
|-----------------------|---------------------------------|

Reporting group description:

In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B were to receive aflibercept 2 milligrams (mg) administered by intravitreal (IVT) injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).

|                       |                                                |
|-----------------------|------------------------------------------------|
| Reporting group title | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) |
|-----------------------|------------------------------------------------|

Reporting group description:

In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).

|                       |                                                  |
|-----------------------|--------------------------------------------------|
| Reporting group title | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|-----------------------|--------------------------------------------------|

Reporting group description:

In Part 2 (from Week 24 to Week 72), participants received faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure was to be administered during study visits at which no faricimab treatment was administered (according to the PTI dosing regimen).

| Serious adverse events                                              | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) |
|---------------------------------------------------------------------|-------------------------------|---------------------------------|------------------------------------------------|
| Total subjects affected by serious adverse events                   |                               |                                 |                                                |
| subjects affected / exposed                                         | 12 / 276 (4.35%)              | 17 / 274 (6.20%)                | 29 / 270 (10.74%)                              |
| number of deaths (all causes)                                       | 1                             | 0                               | 1                                              |
| number of deaths resulting from adverse events                      | 1                             | 0                               | 1                                              |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                               |                                 |                                                |
| Pancreatic carcinoma                                                |                               |                                 |                                                |

|                                                      |                 |                 |                 |
|------------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                          | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Breast cancer                                        |                 |                 |                 |
| subjects affected / exposed                          | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Non-small cell lung cancer metastatic                |                 |                 |                 |
| subjects affected / exposed                          | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Pancreatic neoplasm                                  |                 |                 |                 |
| subjects affected / exposed                          | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostate cancer metastatic                           |                 |                 |                 |
| subjects affected / exposed                          | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Breast cancer recurrent                              |                 |                 |                 |
| subjects affected / exposed                          | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Surgical and medical procedures                      |                 |                 |                 |
| Shoulder arthroplasty                                |                 |                 |                 |
| subjects affected / exposed                          | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| General disorders and administration site conditions |                 |                 |                 |
| Pain                                                 |                 |                 |                 |
| subjects affected / exposed                          | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Death                                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vascular stent stenosis                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Reproductive system and breast disorders        |                 |                 |                 |
| Uterine polyp                                   |                 |                 |                 |
| subjects affected / exposed                     | 1 / 276 (0.36%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Urogenital prolapse                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cervical polyp                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 276 (0.36%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders |                 |                 |                 |
| Acute respiratory failure                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Chronic obstructive pulmonary disease           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Acute pulmonary oedema                          |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pulmonary embolism                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Product issues                                  |                 |                 |                 |
| Device malfunction                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Investigations                                  |                 |                 |                 |
| Blood pressure increased                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                 |                 |
| Fall                                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subdural haematoma                              |                 |                 |                 |
| subjects affected / exposed                     | 1 / 276 (0.36%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lumbar vertebral fracture                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Sternal fracture                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Hip fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 2 / 270 (0.74%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Femur fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Comminuted fracture                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Burns third degree                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ulna fracture                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Congenital, familial and genetic disorders      |                 |                 |                 |
| Vertebral artery hypoplasia                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |
| Acute myocardial infarction                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 2 / 274 (0.73%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 2           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Myocardial infarction                           |                 |                 |                 |
| subjects affected / exposed                     | 1 / 276 (0.36%) | 0 / 274 (0.00%) | 2 / 270 (0.74%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Coronary artery disease                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 2 / 274 (0.73%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 2           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Atrial fibrillation                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Arteriosclerosis coronary artery                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Angina pectoris                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Angina unstable                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 2 / 270 (0.74%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac failure                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac failure congestive                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| Carotid artery stenosis                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cerebral infarction                             |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 3 / 276 (1.09%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 2 / 3           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Multiple sclerosis                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cerebrovascular accident                        |                 |                 |                 |
| subjects affected / exposed                     | 1 / 276 (0.36%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 1           | 0 / 0           | 0 / 0           |
| Cerebral thrombosis                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cerebral haematoma                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hypertensive encephalopathy                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Intracranial aneurysm                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ischaemic stroke                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Sciatica                                        |                 |                 |                 |



|                                                 |                                                       |                 |                 |
|-------------------------------------------------|-------------------------------------------------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Ear and labyrinth disorders                     |                                                       |                 |                 |
| Vertigo positional                              |                                                       |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Eye disorders                                   |                                                       |                 |                 |
| Vitreous haemorrhage                            | Additional description: AEs occurred in the study eye |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Retinal vein occlusion                          | Additional description: AEs occurred in the study eye |                 |                 |
| subjects affected / exposed                     | 1 / 276 (0.36%)                                       | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1                                                 | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Retinal ischaemia                               | Additional description: AEs occurred in the study eye |                 |                 |
| subjects affected / exposed                     | 2 / 276 (0.72%)                                       | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2                                                 | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Cataract                                        | Additional description: AEs occurred in the study eye |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Macular ischaemia                               | Additional description: AEs occurred in the study eye |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Macular oedema                                  | Additional description: AEs occurred in the study eye |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Tractional retinal detachment                   | Additional description: AEs occurred in the study eye |                 |                 |

|                                                 |                                                       |                 |                 |
|-------------------------------------------------|-------------------------------------------------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Rhegmatogenous retinal detachment               | Additional description: AEs occurred in the study eye |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Retinal neovascularisation                      | Additional description: AEs occurred in the study eye |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                                                       |                 |                 |
| Pancreatitis acute                              |                                                       |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Gastric haemorrhage                             |                                                       |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Functional gastrointestinal disorder            |                                                       |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Colitis                                         |                                                       |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%)                                       | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0                                                 | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                                                       |                 |                 |
| Cholecystitis acute                             |                                                       |                 |                 |
| subjects affected / exposed                     | 1 / 276 (0.36%)                                       | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1                                                 | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0                                                 | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders          |                                                       |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Skin ulcer                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| Glomerulonephritis                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Acute kidney injury                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Chronic kidney disease                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Haematuria                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal mass                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Intervertebral disc protrusion                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 2 / 270 (0.74%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 3           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Osteoarthritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Spinal osteoarthritis                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                     |                 |                 |                 |
| Gastroenteritis                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| COVID-19 pneumonia                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| COVID-19                                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 1 / 274 (0.36%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Sepsis                                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Intestinal sepsis                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Herpes zoster                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal infection                      |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Metabolism and nutrition disorders              |                 |                 |                 |
| Type 2 diabetes mellitus                        |                 |                 |                 |
| subjects affected / exposed                     | 1 / 276 (0.36%) | 0 / 274 (0.00%) | 0 / 270 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Diabetes mellitus inadequate control            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 276 (0.00%) | 0 / 274 (0.00%) | 1 / 270 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                                     |                                                  |  |  |
|---------------------------------------------------------------------|--------------------------------------------------|--|--|
| <b>Serious adverse events</b>                                       | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |  |  |
| Total subjects affected by serious adverse events                   |                                                  |  |  |
| subjects affected / exposed                                         | 26 / 267 (9.74%)                                 |  |  |
| number of deaths (all causes)                                       | 2                                                |  |  |
| number of deaths resulting from adverse events                      | 2                                                |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                                  |  |  |
| Pancreatic carcinoma                                                |                                                  |  |  |
| subjects affected / exposed                                         | 0 / 267 (0.00%)                                  |  |  |
| occurrences causally related to treatment / all                     | 0 / 0                                            |  |  |
| deaths causally related to treatment / all                          | 0 / 0                                            |  |  |
| Breast cancer                                                       |                                                  |  |  |
| subjects affected / exposed                                         | 1 / 267 (0.37%)                                  |  |  |
| occurrences causally related to treatment / all                     | 0 / 1                                            |  |  |
| deaths causally related to treatment / all                          | 0 / 0                                            |  |  |
| Non-small cell lung cancer metastatic                               |                                                  |  |  |
| subjects affected / exposed                                         | 1 / 267 (0.37%)                                  |  |  |
| occurrences causally related to treatment / all                     | 0 / 1                                            |  |  |
| deaths causally related to treatment / all                          | 0 / 0                                            |  |  |
| Pancreatic neoplasm                                                 |                                                  |  |  |

|                                                      |                 |  |  |
|------------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                          | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1           |  |  |
| deaths causally related to treatment / all           | 0 / 0           |  |  |
| Prostate cancer metastatic                           |                 |  |  |
| subjects affected / exposed                          | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0           |  |  |
| deaths causally related to treatment / all           | 0 / 0           |  |  |
| Breast cancer recurrent                              |                 |  |  |
| subjects affected / exposed                          | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1           |  |  |
| deaths causally related to treatment / all           | 0 / 0           |  |  |
| Surgical and medical procedures                      |                 |  |  |
| Shoulder arthroplasty                                |                 |  |  |
| subjects affected / exposed                          | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0           |  |  |
| deaths causally related to treatment / all           | 0 / 0           |  |  |
| General disorders and administration site conditions |                 |  |  |
| Pain                                                 |                 |  |  |
| subjects affected / exposed                          | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0           |  |  |
| deaths causally related to treatment / all           | 0 / 0           |  |  |
| Death                                                |                 |  |  |
| subjects affected / exposed                          | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1           |  |  |
| deaths causally related to treatment / all           | 0 / 1           |  |  |
| Vascular stent stenosis                              |                 |  |  |
| subjects affected / exposed                          | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1           |  |  |
| deaths causally related to treatment / all           | 0 / 0           |  |  |
| Reproductive system and breast disorders             |                 |  |  |
| Uterine polyp                                        |                 |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Urogenital prolapse                             |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cervical polyp                                  |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Respiratory, thoracic and mediastinal disorders |                 |  |  |
| Acute respiratory failure                       |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Chronic obstructive pulmonary disease           |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Acute pulmonary oedema                          |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Pulmonary embolism                              |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Product issues                                  |                 |  |  |
| Device malfunction                              |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| Investigations                                  |                 |  |  |
| Blood pressure increased                        |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Injury, poisoning and procedural complications  |                 |  |  |
| Fall                                            |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Subdural haematoma                              |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Lumbar vertebral fracture                       |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Sternal fracture                                |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Hip fracture                                    |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Femur fracture                                  |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Comminuted fracture                             |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |



|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| Burns third degree                              |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Ulna fracture                                   |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Congenital, familial and genetic disorders      |                 |  |  |
| Vertebral artery hypoplasia                     |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cardiac disorders                               |                 |  |  |
| Acute myocardial infarction                     |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Myocardial infarction                           |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Coronary artery disease                         |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 1           |  |  |
| Atrial fibrillation                             |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Arteriosclerosis coronary artery                |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| Angina pectoris                                 |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Angina unstable                                 |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cardiac failure                                 |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cardiac failure congestive                      |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Nervous system disorders                        |                 |  |  |
| Carotid artery stenosis                         |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cerebral infarction                             |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 1 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Multiple sclerosis                              |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cerebrovascular accident                        |                 |  |  |
| subjects affected / exposed                     | 2 / 267 (0.75%) |  |  |
| occurrences causally related to treatment / all | 0 / 2           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cerebral thrombosis                             |                 |  |  |

|                                                 |                                                       |  |  |
|-------------------------------------------------|-------------------------------------------------------|--|--|
| subjects affected / exposed                     | 1 / 267 (0.37%)                                       |  |  |
| occurrences causally related to treatment / all | 1 / 1                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Cerebral haematoma                              |                                                       |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 1                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Hypertensive encephalopathy                     |                                                       |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Intracranial aneurysm                           |                                                       |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Ischaemic stroke                                |                                                       |  |  |
| subjects affected / exposed                     | 2 / 267 (0.75%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 2                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Sciatica                                        |                                                       |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Ear and labyrinth disorders                     |                                                       |  |  |
| Vertigo positional                              |                                                       |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 1                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Eye disorders                                   |                                                       |  |  |
| Vitreous haemorrhage                            | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Retinal vein occlusion                          | Additional description: AEs occurred in the study eye |  |  |

|                                                 |                                                       |  |  |
|-------------------------------------------------|-------------------------------------------------------|--|--|
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Retinal ischaemia                               | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed                     | 2 / 267 (0.75%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 2                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Cataract                                        | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 1                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Macular ischaemia                               | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Macular oedema                                  | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Tractional retinal detachment                   | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Rhegmatogenous retinal detachment               | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Retinal neovascularisation                      | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%)                                       |  |  |
| occurrences causally related to treatment / all | 0 / 0                                                 |  |  |
| deaths causally related to treatment / all      | 0 / 0                                                 |  |  |
| Gastrointestinal disorders                      |                                                       |  |  |
| Pancreatitis acute                              |                                                       |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Gastric haemorrhage                             |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Functional gastrointestinal disorder            |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Colitis                                         |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Hepatobiliary disorders                         |                 |  |  |
| Cholecystitis acute                             |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Skin and subcutaneous tissue disorders          |                 |  |  |
| Skin ulcer                                      |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Renal and urinary disorders                     |                 |  |  |
| Glomerulonephritis                              |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Acute kidney injury                             |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| Chronic kidney disease                          |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Haematuria                                      |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Renal mass                                      |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Musculoskeletal and connective tissue disorders |                 |  |  |
| Intervertebral disc protrusion                  |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Osteoarthritis                                  |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Spinal osteoarthritis                           |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Infections and infestations                     |                 |  |  |
| Gastroenteritis                                 |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| COVID-19 pneumonia                              |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| COVID-19                                        |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Sepsis                                          |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Pyelonephritis                                  |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Intestinal sepsis                               |                 |  |  |
| subjects affected / exposed                     | 1 / 267 (0.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Herpes zoster                                   |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Gastrointestinal infection                      |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Metabolism and nutrition disorders              |                 |  |  |
| Type 2 diabetes mellitus                        |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Diabetes mellitus inadequate control            |                 |  |  |
| subjects affected / exposed                     | 0 / 267 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |

Frequency threshold for reporting non-serious adverse events: 3 %

| Non-serious adverse events                            | Arm A: Faricimab<br>Q4W (Part 1)                      | Arm B: Aflibercept<br>Q4W (Part 1) | Arm A: Faricimab<br>Q4W to Faricimab<br>PTI (Part 2) |
|-------------------------------------------------------|-------------------------------------------------------|------------------------------------|------------------------------------------------------|
| Total subjects affected by non-serious adverse events |                                                       |                                    |                                                      |
| subjects affected / exposed                           | 62 / 276 (22.46%)                                     | 69 / 274 (25.18%)                  | 92 / 270 (34.07%)                                    |
| Investigations                                        |                                                       |                                    |                                                      |
| Intraocular pressure increased                        | Additional description: AEs occurred in the study eye |                                    |                                                      |
| subjects affected / exposed                           | 1 / 276 (0.36%)                                       | 8 / 274 (2.92%)                    | 13 / 270 (4.81%)                                     |
| occurrences (all)                                     | 2                                                     | 8                                  | 21                                                   |
| Vascular disorders                                    |                                                       |                                    |                                                      |
| Hypertension                                          |                                                       |                                    |                                                      |
| subjects affected / exposed                           | 20 / 276 (7.25%)                                      | 7 / 274 (2.55%)                    | 14 / 270 (5.19%)                                     |
| occurrences (all)                                     | 21                                                    | 7                                  | 14                                                   |
| Eye disorders                                         |                                                       |                                    |                                                      |
| Dry eye                                               | Additional description: AEs occurred in the study eye |                                    |                                                      |
| subjects affected / exposed                           | 5 / 276 (1.81%)                                       | 9 / 274 (3.28%)                    | 4 / 270 (1.48%)                                      |
| occurrences (all)                                     | 5                                                     | 9                                  | 5                                                    |
| Conjunctival haemorrhage                              | Additional description: AEs occurred in the study eye |                                    |                                                      |
| subjects affected / exposed                           | 8 / 276 (2.90%)                                       | 10 / 274 (3.65%)                   | 11 / 270 (4.07%)                                     |
| occurrences (all)                                     | 9                                                     | 11                                 | 11                                                   |
| Vitreous detachment                                   | Additional description: AEs occurred in the study eye |                                    |                                                      |
| subjects affected / exposed                           | 4 / 276 (1.45%)                                       | 2 / 274 (0.73%)                    | 7 / 270 (2.59%)                                      |
| occurrences (all)                                     | 4                                                     | 2                                  | 7                                                    |
| Retinal vein occlusion                                | Additional description: AEs occurred in the study eye |                                    |                                                      |
| subjects affected / exposed                           | 0 / 276 (0.00%)                                       | 2 / 274 (0.73%)                    | 9 / 270 (3.33%)                                      |
| occurrences (all)                                     | 0                                                     | 3                                  | 12                                                   |
| Vitreous floaters                                     | Additional description: AEs occurred in the study eye |                                    |                                                      |
| subjects affected / exposed                           | 7 / 276 (2.54%)                                       | 6 / 274 (2.19%)                    | 0 / 270 (0.00%)                                      |
| occurrences (all)                                     | 7                                                     | 6                                  | 0                                                    |
| Cataract                                              | Additional description: AEs occurred in the study eye |                                    |                                                      |
| subjects affected / exposed                           | 2 / 276 (0.72%)                                       | 1 / 274 (0.36%)                    | 9 / 270 (3.33%)                                      |
| occurrences (all)                                     | 2                                                     | 1                                  | 9                                                    |
| Macular oedema                                        | Additional description: AEs occurred in the study eye |                                    |                                                      |
| subjects affected / exposed                           | 1 / 276 (0.36%)                                       | 2 / 274 (0.73%)                    | 10 / 270 (3.70%)                                     |
| occurrences (all)                                     | 1                                                     | 2                                  | 11                                                   |
| Musculoskeletal and connective tissue                 |                                                       |                                    |                                                      |



|                                   |                  |                  |                   |
|-----------------------------------|------------------|------------------|-------------------|
| disorders                         |                  |                  |                   |
| Back pain                         |                  |                  |                   |
| subjects affected / exposed       | 2 / 276 (0.72%)  | 10 / 274 (3.65%) | 5 / 270 (1.85%)   |
| occurrences (all)                 | 2                | 10               | 6                 |
| Infections and infestations       |                  |                  |                   |
| COVID-19                          |                  |                  |                   |
| subjects affected / exposed       | 10 / 276 (3.62%) | 16 / 274 (5.84%) | 32 / 270 (11.85%) |
| occurrences (all)                 | 10               | 16               | 32                |
| Nasopharyngitis                   |                  |                  |                   |
| subjects affected / exposed       | 6 / 276 (2.17%)  | 6 / 274 (2.19%)  | 7 / 270 (2.59%)   |
| occurrences (all)                 | 6                | 6                | 8                 |
| Upper respiratory tract infection |                  |                  |                   |
| subjects affected / exposed       | 4 / 276 (1.45%)  | 5 / 274 (1.82%)  | 6 / 270 (2.22%)   |
| occurrences (all)                 | 4                | 5                | 8                 |

|                                                       |                                                        |  |  |
|-------------------------------------------------------|--------------------------------------------------------|--|--|
| <b>Non-serious adverse events</b>                     | Arm B: Aflibercept<br>Q4W to Faricimab<br>PTI (Part 2) |  |  |
| Total subjects affected by non-serious adverse events |                                                        |  |  |
| subjects affected / exposed                           | 87 / 267 (32.58%)                                      |  |  |
| Investigations                                        |                                                        |  |  |
| Intraocular pressure increased                        | Additional description: AEs occurred in the study eye  |  |  |
| subjects affected / exposed                           | 8 / 267 (3.00%)                                        |  |  |
| occurrences (all)                                     | 11                                                     |  |  |
| Vascular disorders                                    |                                                        |  |  |
| Hypertension                                          |                                                        |  |  |
| subjects affected / exposed                           | 8 / 267 (3.00%)                                        |  |  |
| occurrences (all)                                     | 8                                                      |  |  |
| Eye disorders                                         |                                                        |  |  |
| Dry eye                                               | Additional description: AEs occurred in the study eye  |  |  |
| subjects affected / exposed                           | 4 / 267 (1.50%)                                        |  |  |
| occurrences (all)                                     | 4                                                      |  |  |
| Conjunctival haemorrhage                              | Additional description: AEs occurred in the study eye  |  |  |
| subjects affected / exposed                           | 10 / 267 (3.75%)                                       |  |  |
| occurrences (all)                                     | 11                                                     |  |  |
| Vitreous detachment                                   | Additional description: AEs occurred in the study eye  |  |  |
| subjects affected / exposed                           | 9 / 267 (3.37%)                                        |  |  |
| occurrences (all)                                     | 9                                                      |  |  |
| Retinal vein occlusion                                | Additional description: AEs occurred in the study eye  |  |  |

|                                                  |                                                       |  |  |
|--------------------------------------------------|-------------------------------------------------------|--|--|
| subjects affected / exposed<br>occurrences (all) | 8 / 267 (3.00%)<br>10                                 |  |  |
| Vitreous floaters                                | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed<br>occurrences (all) | 9 / 267 (3.37%)<br>9                                  |  |  |
| Cataract                                         | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed<br>occurrences (all) | 9 / 267 (3.37%)<br>9                                  |  |  |
| Macular oedema                                   | Additional description: AEs occurred in the study eye |  |  |
| subjects affected / exposed<br>occurrences (all) | 5 / 267 (1.87%)<br>8                                  |  |  |
| Musculoskeletal and connective tissue disorders  |                                                       |  |  |
| Back pain                                        |                                                       |  |  |
| subjects affected / exposed<br>occurrences (all) | 4 / 267 (1.50%)<br>4                                  |  |  |
| Infections and infestations                      |                                                       |  |  |
| COVID-19                                         |                                                       |  |  |
| subjects affected / exposed<br>occurrences (all) | 25 / 267 (9.36%)<br>25                                |  |  |
| Nasopharyngitis                                  |                                                       |  |  |
| subjects affected / exposed<br>occurrences (all) | 10 / 267 (3.75%)<br>12                                |  |  |
| Upper respiratory tract infection                |                                                       |  |  |
| subjects affected / exposed<br>occurrences (all) | 9 / 267 (3.37%)<br>11                                 |  |  |

**More information**

**Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17 November 2020 | Protocol version 2, the summary of major changes from protocol version 1 were:<br>-Due to extenuating circumstances, such as the Coronavirus Disease 2019 (COVID-19) pandemic, patients may not have had the ability to complete certain trial activities, therefore, in order to ensure adequate power for the primary endpoint, the sample size was increased to mitigate the loss of patients, loss of data, and the potential impact of protocol deviations affecting efficacy analyses.;<br>-Clarified that missed mandatory pharmacokinetic (PK), pharmacodynamic (PD), or anti-drug antibody (ADA) samples be obtained at the next scheduled visit the patient attended.;<br>-Clarified administration guidelines of the National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) to include interviews over the telephone. |

Notes:

---

**Interruptions (globally)**

Were there any global interruptions to the trial? No

**Limitations and caveats**

None reported